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α-Synuclein pathology has been hypothesized to propagate in synucleinopathies by 
intercellular transfer of pathogenic seeds in a prion-like fashion. Extracellular release of 
α-Synuclein via small extracellular vesicles has been proposed as one of the mechanisms of 
cell-to-cell disease transmission. In vitro, extracellular α-Synuclein has been detected in 
exosomal vesicles and we have recently provided evidence that α-Synuclein is present in 
exosomes in the central nervous system in vivo.  
We hypothesized that exosomes from patients with α-Synuclein related neurodegeneration 
serve as carriers for interneuronal disease transfer. In this study, we purified exosomes from 
cerebrospinal fluid from patients with synucleinopathies including Parkinson`s disease and 
dementia with Lewy bodies, progressive supranuclear palsy as an example of a disease that 
clinically overlaps with Parkinson`s disease but without underlying α-Synuclein pathology 
and other neurological controls without neurodegenerative diseases. Exosome numbers and 
exosomal α-Synuclein levels were quantified and their potential to induce aggregation of 
soluble α-Synuclein was evaluated. We observed differences in cerebrospinal fluid exosomal 
α-Synuclein levels between patients with Parkinson`s disease and dementia with Lewy 
bodies and between dementia with Lewy bodies and controls. In addition, exosomal 
α-Synuclein levels correlated with cognitive decline and Tau levels as a marker of 
neurodegeneration in dementia with Lewy bodies. By analyzing exosomal α-Synuclein levels 
and exosome numbers, we were able to distinguish Parkinson`s disease from dementia with 
Lewy bodies and controls as well as dementia with Lewy bodies from Parkinson`s disease 
and controls with high sensitivity and specificity. Importantly, cerebrospinal fluid exosomes 
from Parkinson`s disease and dementia with Lewy bodies disease patients induced 
aggregation of α-Synuclein in a reporter cell model, dependent on the amount of exosomal 
α-Synuclein. Thus, exosomal α-Synuclein could serve as a diagnostic biomarker for 
α-Synuclein related neurodegenerative diseases and as a progression marker in dementia 
with Lewy bodies.  
These findings further indicate that cerebrospinal fluid derived exosomes from patients with 
Parkinson`s disease and dementia with Lewy bodies contain a pathogenic α-Synuclein 
species, which induces aggregation of endogenous α-Synuclein in recipient neurons and 
therefore could transmit disease pathology.  
Summary| XII 
 
Since multiple recent therapy trials in Alzheimer`s disease have failed and therapeutic 
interventions are most promising in early and even preclinical stages, the accurate 
identification of patients with Alzheimer`s disease is indispensable. Therefore, diagnostic 
and prognostic biomarkers are required and identification of such markers would also give 
insight into the underlying molecular mechanisms of Alzheimer`s disease pathology. 
Accumulating evidence suggests that dysregulation of processes, which physiologically 
regulate gene expression, plays an important role in the pathogenesis of neurodegenerative 
diseases. Additionally, dysregulation of small non-coding RNAs in Alzheimer`s disease brain 
has been shown in various studies.  
In our second study, we analyzed the small non-coding RNA composition of exosomes 
derived from human cerebrospinal fluid in order to test whether exosomal small non-coding 
RNA profiles can be used as a disease signature for Alzheimer`s disease. 
Here, we show that genome-wide profiling of cerebrospinal fluid exosomal small non-coding 
RNA expression reveals a specific small RNA signature which differentiates Alzheimer`s 
disease from cognitive healthy controls. Thus, our selected set of exosomal small non-coding 
RNAs could be used as a potential biomarker in the future, replication in a larger validation 
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1. Introduction 
1.1. Extracellular vesicles 
Extracellular vesicles (EVs) are membrane vesicles which are secreted from prokaryotic and 
eukaryotic cells into the extracellular space. According to their subcellular origin, they can be 
divided into several subclasses. Exosomes are 30 – 100 nm in diameter, generated within the 
endosomal system and secreted into the extracellular space upon fusion of late endosomes 
with the plasma membrane, first described during reticulocyte maturation (Harding et al., 
1983; Johnstone et al., 1987; Pan et al., 1985). Shedding vesicles display another class of EVs 
and originate from the plasma membrane. This EV population includes microvesicles (MVs) 
with a heterogenous shape and size of approximately 50 – 1000 nm and apoptotic bodies or 
blebs, which are generally larger and display a size range of 1 – 4 µm (Schneider and Simons, 
2013). The latter are released from dying cells during apoptotic processes.  
It has been shown by now that many different cell types release EVs including cells of 
hematopoetic origin, e.g. B-lymphocytes and dendritic cells (DCs) (Raposo et al., 1996; 
Zitvogel et al., 1998) but also other cells, such as neurons (Faure et al., 2006), 
oligodendrocytes (Kramer-Albers et al., 2007) and intestinal epithelial cells (van Niel et al., 
2001). Moreover, EVs were identified and isolated from diverse body fluids such as urine, 
blood (plasma and serum), saliva and cerebrospinal fluid (CSF) (Caby et al., 2005; Palanisamy 
et al., 2010; Pisitkun et al., 2004; Street et al., 2012), thus demonstrating their secretion in 
vivo.  
 
1.1.1. Biogenesis and extracellular release of exosomes 
Exosomes are generated along the endocytic pathway which comprises the uptake of 
extracellular or cellular cargo into early endosomes and further sorting to the degradation or 
to the recycling pathway (Gould and Lippincott-Schwartz, 2009). During maturation from 
early endosomes to late endosomes (Stoorvogel et al., 1991), intraluminal vesicles (ILVs) are 
formed by inward budding of the endosomal membrane (Figure 1.1). The lumina of these 
endosomes are then filled with ILVs, a characteristic feature giving them the name 
multivesicular bodies (MVBs). During the process of ILV formation, proteins, lipids and 
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nucleic acids are sorted into the vesicles. Depending on their fate, MVBs fuse with the 
lysosome for the degradation of their cargo or they fuse with the plasma membrane to 
release their ILVs into the extracellular space (Colombo et al., 2014). Released ILVs are then 




Figure 1.1: Biogenesis and release of exosomes from eukaryotic cells. Intraluminal vesicles (ILVs) are formed 
by invagination of the membrane of early endosomes and further budding into the endosomal lumen. 
Endosomal compartments filled with ILVs are named multivesicular bodies (MVB) and several molecules as 
ESCRT machinery proteins, tetraspanins and cermamide lipids might be involved in the biogenesis of ILVs. 
Depending on their fate, MVBs can fuse either with the lysosome for intracellular degradation or with the 
plasma membrane to secrete their ILVs as exosomes into the extracellular space. Several Rab proteins seem to 
be involved in the transport process of MVBs to the plasma membrane. In contrast, MVs bud directly from the 
plasma membrane. Adopted and modified image from Kowal et al. (2014). 
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1.1.1.1. ESCRT-dependent exosome biogenesis  
The molecular mechanism for the formation of ILVs is driven by the endosomal sorting 
complex required for transport (ESCRT) machinery (Williams and Urbe, 2007). The complex is 
organized by four multiprotein subcomplexes named ESCRT-0, -I, -II, and -III and associated 
proteins such as Alix and VPS4. The ESCRT-0, -I and -II complexes are responsible for the 
recognition and recruitment of ubiquitinated proteins in the endosomal membrane and are 
involved in membrane deformation (Babst et al., 2002b; Katzmann et al., 2001; Mayers et 
al., 2011). Further budding and vesicle scission is then mediated by ESCRT-III components 
followed by the recruitment of the VPS4 ATPase that drives disassembly and recycling of the 
ESCRT components (Babst et al., 2002a). It has been also argued whether VPS4 directly 
contributes to ILV scission (Babst, 2011; Henne et al., 2011). The enrichment of the ESCRT 
associated proteins Alix and Tsg101 in exosome preparations (Thery et al., 2001) strengthen 
the assumption that the biogenesis of exosomes is processed by the ESCRT pathway. 
However, several studies discussed the hypothesis of involvement of ESCRT-independent 
mechanisms in the formation of ILVs and exosome biogenesis. 
 
1.1.1.2. ESCRT-independent exosome biogenesis and protein sorting 
ESCRT-independent mechanism of ILV formation and ILV sorting of proteins was proposed 
based on the finding that ILV and MVB formation as well as exosomal protein release still 
take place when ESCRT subcomplexes are inactivated (Stuffers et al., 2009). Besides ESCRT 
mediated sorting, several mechanisms of ILV formation and protein loading into ILVs have 
been described, which involve lipids, tetraspanins or heat shock proteins. 
Lipid dependent mechanisms 
Trajkovic and co-workers demonstrated that sorting of proteolipid protein PLP into ILVs is 
not mediated via ESCRT proteins but instead requires the synthesis of the sphingolipid 
ceramide in an oligodendroglial cell line. The authors showed that the cone-shaped 
ceramide induced the inward budding of the endosomal membrane (Trajkovic et al., 2008). 
Exosomes contain lipid-enriched microdomains composed of cholesterol and 
glycosphingolipids termed lipid rafts which were suggested to be involved in targeting of 
lipid raft associated proteins to exosomes (de Gassart et al., 2003). 
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Strauss et al. (2010) additionally showed that cholesterol increases the release of exosomes 
in a flotillin-dependent manner. 
Tetraspanin dependent mechanisms 
Sorting of premelanosomal protein PMEL into ILVs, in human melanoma cells, is not driven 
by ceramide and does not require the ESCRT pathway, but is regulated by interaction of 
PMEL with the tetraspanin CD63 (van Niel et al., 2011). Moreover, an alternative mechanism 
was reported in which budding of CD63 positive ILVs into MVBs, including protein packaging, 
is controlled by the interaction of syntenin with Alix dependent on heparan sulfate and 
several ESCRT proteins (Baietti et al., 2012).  
Expression of the tetraspanin TSPAN8 resulted in modified exosomal mRNA content and 
protein composition in rat adenocarcinoma cells (Nazarenko et al., 2010) and CD81 enriched 
microdomains were shown to target certain ligands to exosomes (Perez-Hernandez et al., 
2013). 
Heat shock proteins 
It was demonstrated that the chaperone HSC70 recruits the transferrin receptor to 
exosomes through a specific binding sequence in the receptor (Geminard et al., 2004). 
Oligomerization dependent mechanisms 
Moreover, an alternative process that facilitates exosomal sorting was reported in Jurkat T 
cells, where plasma membrane proteins were targeted to exosomes through higher-order 
protein oligomerization (Fang et al., 2007). Similarily, antibody-induced cross-linking of 
membrane proteins enhanced their incorporation into exosomes as reported for the 
transferrin receptor in reticulocytes (Vidal et al., 1997) and for major histocompatibility 
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Release of exosomes 
The release of ILVs into the extracellular space as exosomes comprises the guidance of MVBs 
to the plasma membrane and the docking and fusion of the MVB membrane with the plasma 
membrane. MVB trafficking is mainly mediated by proteins of the cytoskeleton (actin and 
microtubules) and Rab family small GTPase proteins, which have been identified as 
important mediators of intracellular vesicle transport and docking events (Stenmark, 2009). 
Rab11 was the first family member that was observed to be involved in exosome release 
(Savina et al., 2005; Savina et al., 2002). Rab27 (Ostrowski et al., 2010) and Rab35 (Hsu et al., 
2010) were also shown to control secretion of exosomes in different cell types. Since Rab11 
and Rab35 associate to early and recycling endosomes whereas Rab27 is mainly found in late 
endosomes, it was hypothesized that different subtypes of exosomal vesicles exist, with 
some of them being released from early or recycling endosomes and some from late 
endosomes (Figure 1.1) (Colombo et al., 2014). The final fusion machinery includes soluble 
N-ethylmaleimide-sensitive-factor attachment protein receptor (SNARE) proteins localized to 
both, the MVB and the plasma membrane, which then form complexes to facilitate 
membrane fusion (Fader et al., 2009; Gross et al., 2012).  
 
1.1.2. Biophysical properties of exosomes 
Exosomes are characterized by their morphology, size, density and molecular composition 
and these properties are commonly used to discriminate them from other EVs. The 
morphology and size of exosomes were intensively studied by subjecting purified exosome 
preparations to electron microscopy (EM), where they appear as 40 – 120 nm vesicles 
encapsulated by a lipid bilayer. They exhibit a cup-shaped form (Raposo et al., 1996), which 
was later identified as a methodically induced artifact due to collapsing of the vesicle 
membrane. However, by using cryo-EM it has been demonstrated, that the natural 
appearance of exosomes is a round shape (Conde-Vancells et al., 2008; Raposo and 
Stoorvogel, 2013). As all lipid-containing vesicles, exosomes have the ability to float in 
sucrose gradients with reported densities of 1.13 g/ml to 1.19 g/ml (Thery et al., 2006) 
whereas bigger vesicles as apoptotic bodies float at higher densities ranging from 1.24 –
 1.28 g/ml (Thery et al., 2001). 
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1.1.3. Nucleic acids in exosomes 
In addition to their protein and lipid content, exosomes contain messenger RNA (mRNA) and 
small non-coding RNA species (ncRNA) as first reported by Valadi et al. (2007). These authors 
and others could show that exosomal mRNA and micro RNA (miRNA) molecules can be 
transported to host cells where they can modulate protein expression levels. (Mittelbrunn et 
al., 2011; Skog et al., 2008; Valadi et al., 2007). Next-generation sequencing (NGS) of 
exosomal RNA content revealed the presence of mRNA, small ncRNA species as miRNA, piwi-
interacting RNA (piRNA), small nucleolar RNA (snoRNA) and small nuclear RNA (snRNA) as 
well as transfer RNAs (tRNA) within exosome preparations (Bellingham et al., 2012a; Cheng 
et al., 2014b; Huang et al., 2013; Nolte-'t Hoen et al., 2012). Exosomes can be enriched in 
certain RNA species compared to cellular RNA and their RNA composition can be distinct 
from the one of the parental cell, indicating specific targeting to sort RNAs into exosomes 
(Guduric-Fuchs et al., 2012; Montecalvo et al., 2012). However, as exosomes derived from 
various cell types were found to carry similar miRNA cargo, a common mechanism for 
targeting miRNAs to exosomes could also exist (Guduric-Fuchs et al., 2012). 
 
1.1.3.1. Exosomal RNA sorting 
While the loading of specific RNA species into exosomes is not fully clarified, several 
molecular mechanisms have been proposed. One process involves specific lipid-raft like 
structures within the endosomal membrane, which promote the binding of cytosolic RNA 
molecules depending on their affinity (Janas et al., 2015). The affinity of a RNA molecule to 
bind to lipid bilayers is probably given by a specific membrane binding motif within the RNA 
sequence as suggested for miRNA (Villarroya-Beltri et al., 2013) and mRNA molecules 
(Batagov et al., 2011). In addition, hydrophobic modifications of RNA molecules were shown 
to enhance the affinity of tRNAs to raft-like structures (Janas and Yarus, 2012) suggesting an 
alternative recognition signal. There is also evidence of involvement of RNA-binding proteins 
in the incorporation processes of RNAs as described by Villarroya-Beltri et al. (2013). Here, 
the heterogenous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) was found to control the 
loading of miRNAs into exosomes through binding to short RNA sequence motifs. 
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1.1.4. Function of exosomes 
1.1.4.1. Physiological function of exosomes 
Initially, exosomes were considered as cellular garbage cans to discard unnecessary or 
obsolete plasma membrane or cytoplasmic proteins (Johnstone et al., 1987). It was shown 
that the transferrin receptor is transported from the plasma membrane to the extracellular 
space by a MVB/exosome involved mechanism during the maturation of reticulocytes into 
erythrocytes (Chitambar et al., 1991; Johnstone et al., 1987). In 1996, Raposo et al. proposed 
for the first time a signaling role of exosomes in cell-to-cell communication when they 
demonstrated that B lymphocytes secrete MHC II enriched exosomes leading to the specific 
activation of CD4+ T cells and therefore mediate immune response (Raposo et al., 1996). 
Furthermore, exosomes can trigger immune response by activating immune cells including 
direct peptide/MHC complex presentation to T cells or DCs or antigen transfer to DCs. 
Inhibitory effects on immume response mediated by exosomes include inhibition of T cell 
activation, inhibition of T cell and natural killer cell cytotoxicity and promotion of regulatory 
T cell activity (Thery et al., 2009). In addition, exosomes were discussed to be involved in 
morphogenesis processes due to their association to Wnt (Beckett et al., 2013; Luga et al., 
2012), thus confirming their function on signal transduction.  
Moreover, multiple studies focused on potential functions of exosomes in the central 
nervous system (CNS). It has been observed that multiple cell types, as neurons, 
oligodendroglial cells and microglia release exosomes which might be transferred to target 
cells (Faure et al., 2006; Kramer-Albers et al., 2007; Lachenal et al., 2011). Secreted 
exosomes from oligodendrocytes are involved in the regulation of myelin formation due to 
an autoinhibitory effect as shown by Bakhti et al. (2011). Exosomes released from glia cells 
were enriched in Synapsin I and appeared to promote neurite outgrowth in hippocampal 
neurons and neuronal survival of cortical neurons under cellular stress conditions (Wang et 
al., 2011). Furthermore, the study from Lachenal et al. (2011) considered a potential role of 
exosomes in synaptic function, since the release of exosomes from the somato-dendritic 
part of cortical neurons is regulated by a Calcium influx and glutamatergic synaptic activity. 
Besides the transfer of proteins, exosomes were shown to transport mRNA molecules which 
are taken up by target cells and are translated into the corresponding proteins or small RNA 
species which act on their target mRNA and thereby interfere and modulate gene 
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expression. Horizontal transfer of genetic information via exosomes as a new mechanism of 
intercellular communication was reported in multiple cell models, such as embryonic stem 
cells (Ratajczak et al., 2006), mast cells (Valadi et al., 2007), glioblastoma cells (Skog et al., 
2008), endothelial cells (Deregibus et al., 2007) or primary cortical neurons (Morel et al., 
2013). 
 
1.1.4.2. Exosomes in pathological processes: Role in neurodegenerative diseases 
In addition to their biological function, exosomes are hypothesized to be involved in various 
pathological processes and disease pathogenesis including cancer, virus infection and 
neurodegenerative diseases such as Alzheimer`s diseases (AD), Parkinson`s disease (PD), 
prion disease and amyotrophic lateral sclerosis (ALS). Despite differences in clinical 
symptoms and molecular pathology, most neurodegenerative diseases share common 
properties, such as oligomerization and aggregation of disease-specific proteins leading to 
intra- or extracellular deposits in the brain. These include, among many others, β-amyloid 
and Tau in AD, α-Synuclein in PD, Prion proteins (PrP) in prion diseases and superoxide 
dismutase (SOD) in ALS. Interestingly, all of these proteins were found to be released from 
cells in association with exosomes in vitro (Emmanouilidou et al., 2010; Fevrier et al., 2004; 
Gomes et al., 2007; Rajendran et al., 2006). A second common feature of these disorders is 
that the protein related pathology spreads throughout the brain over time following 
anatomical connections (Braak and Braak, 1991; Braak et al., 2003; Brettschneider et al., 
2015). Among several alternative modes of action, exosomes were hypothesized to 
contribute to the propagation of pathological protein species by transferring them between 
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Exosomes in Alzheimer`s disease 
The pathological characteristics of AD are represented by insoluble extracellular senile 
plaques composed of accumulated β-amyloid protein (Aβ) and by intracellular tangles 
composed of hyperphosphorylated Tau protein. Aβ is generated by proteolytic processing of 
the transmembrane protein amyloid precursor protein (APP). Interestingly, the APP cleaving 
secretases β- and γ-secretase were not only found at the plasma membrane but also 
localized to early endosomes indicating that Aβ might be synthesized intracellular with the 
endocytic pathway as an important site of generation (Kaether et al., 2006).  
Aβ peptides, C-terminal fragments of APP or even full-length APP were detected in exosomal 
preparations as demonstrated in SY5Y and CHO cells overexpressing wild-type APP (Sharples 
et al., 2008; Vingtdeux et al., 2007) or in HeLa and N2a cells stably expressing the swedish 
mutant of APP (Rajendran et al., 2006). The first in vivo evidence of Aβ associated exosomes 
came from exosome-enriched preparations derived from brains of transgenic mice 
overexpressing human APP where an enrichment of Aβ, full-length and fragmentated APP 
was observed compared to exosome-enriched preparations from wild-type control brains 
(Perez-Gonzalez et al., 2012).  
It is possible that exosome-associated Aβ may help to regulate intracellular Aβ levels. The 
insulin-degrading enzyme, a protease that is involved in the degradation of extracellular Aβ, 
was reported to be sorted and released via exosomes (Bulloj et al., 2010), suggesting that 
exosomes might exhibit a neuroprotective role in AD. Moreover, neuron-derived exosomes 
were observed to promote conformational changes of extracellular Aβ42 into non-toxic 
fibrils and facilitate Aβ uptake and clearance by microglia in vitro (Yuyama et al., 2012). In 
contrast, exosomes derived from primary astrocytes and injected into 5xFAD AD mouse 
brains were reported to promote the aggregation of Aβ42 in vivo (Dinkins et al., 2014). 
However, whether this leads to increased toxicity in neurons was not reported.  
In addition to the presence of Aβ in exosomes, the intracellular hyperphosphorylated Tau 
protein was observed to be exported from Tau overexpressing cells in association with 
exosome-like membrane vesicles (Simon et al., 2012). It was recently demonstrated by using 
a fluorescence resonance energy transfer (FRET) Tau biosensor cell model, that exosome 
enriched fractions prepared from brain tissue of Tau transgenic mice can seed Tau 
aggregation in recipient cells (Polanco et al., 2016). Interestingly, an enrichment of several 
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phosphorylated Tau species, which are known to be implicated in AD pathology, was 
reported in exosomes derived from blood of AD patients compared to controls with further 
specification of neuronal derived exosomes by cell adhesion molecule L1 (L1CAM) 
immunodetection (Fiandaca et al., 2015).  
 
Exosomes in Parkinson`s disease 
The protein pathology in PD and other neurodegenerative diseases including dementia with 
Lewy bodies (DLB) or multiple system atrophy (MSA) is characterized by intracellular 
inclusions named Lewy bodies (LBs), which are mainly composed of aberrantly aggregated 
α-Synuclein protein. Since soluble and aggregated α-Synuclein species were detected in cell 
culture supernatant and body fluids including plasma, CSF and brain interstitial fluid (Borghi 
et al., 2000; El-Agnaf et al., 2003; 2006; Emmanouilidou et al., 2011; Lee et al., 2005; Tokuda 
et al., 2010), it became evident that α-Synuclein can be released from cells which could be 
one potential mechanism of disease propagation between cells. The first evidence of 
exosome mediated α-Synuclein secretion was provided by Emmanouilidou et al. (2010) who 
reported exosomal α-Synuclein release from α-Synuclein overexpressing cells. This was 
further supported by Danzer et al. (2012), who could additionally show that oligomeric 
α-Synuclein is present in exosomes of neuronal cells. We could recently demonstrate for the 
first time that exosomal α-Synuclein exists in vivo by analyzing exosomes derived from 
human CSF (Kunadt et al., 2015). Moreover, exosomes isolated from plasma also contain 
α-Synuclein (Shi et al., 2014). 
In 2011, it was demonstrated that α-Synuclein containing exosomes released from 
α-Synuclein overexpressing SH-SY5Y cells could be transferred to untransfected SH-SY5Y cells 
where they are internalized (Alvarez-Erviti et al., 2011). Moreover, exosomal α-Synuclein 
oligomers are taken up by recipient cells more efficiently compared to free α-Synuclein 
species (Danzer et al., 2012). These results support the hypothesis of exosome mediated 
spreading of α-Synuclein between different cells with a potential transfer of toxic oligomeric 
species. 
It has been shown that the autophagy pathway can modulate exosome release whereby 
induction of autophagy promotes the interaction of MVBs and autophagosomes and thereby 
inhibits exosome release (Fader et al., 2008). Interestingly, sporadic as well as genetic forms 
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of PD are associated with impaired autophagy processes (Damme et al., 2015) and cells 
treated with the autophagy inhibitor bafilomycin in fact released more exosomal α-Synuclein 
(Alvarez-Erviti et al., 2011; Danzer et al., 2012). Poehler and co-workers additionally 
reported that blocking of the autophagy pathway in α-Synuclein expressing H4 cells resulted 
in less intracellular α-Synuclein aggregates but enhanced release of small α-Synuclein 
oligomers via exosomes (Poehler et al., 2014). These studies suggest that α-Synuclein could 
be secreted into the extracellular space via exosomes as an alternative mechanism when 
other cellular degradation pathways are impaired.  
The protein ATP13A2 (also named PARK9), which is linked to an inherited form of PD 
(Ramirez et al., 2006) and is physiologically localized to lysosomes and MVBs, was recently 
shown to be implicated in exosome biogenesis (Kong et al., 2014; Tsunemi et al., 2014). 
ATP13A2 overexpression in H4 cells and mouse cortical neurons led to an increase in 
α-Synuclein secretion via exosomes, whereas loss of function mutations in ATP13A2 resulted 
in decreased exosome secretion due to a reduced number of ILVs in MVBs and thereby 
elevated intracellular α-Synuclein levels (Kong et al., 2014; Tsunemi et al., 2014). 
Interestingly, ATP13A2 mutations are accompanied by decreased protein expression in PD, 
but ATP13A2 protein levels were found to be higher in surviving dopaminergic neurons of 
sporadic PD patients (Dehay et al., 2012). 
 
1.1.5. Purification of EVs 
All currently available methods to purify EVs are generally based on vesicle separation in 
accordance to their biophysical properties including size, morphology and density. The most 
common protocol to purify exosomes from tissue culture supernatants or biological fluids is 
a serial centrifugation step protocol at increasing speeds to remove cellular debris and larger 
plasma membrane derived vesicles followed by sedimentation of exosomes by 
ultracentrifugation (UC) at 100,000 x g (Thery et al., 2006). To overcome problems with co-
purification of protein aggregates of similar size, exosome preparations might be subjected 
to sucrose density gradient UC where they float at characteristic densities (see section 
1.1.2). However, separation of EVs in the size range of exosomes from MVs of similar size is 
impossible.  
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Further isolation methods, which are based on vesicle separation by size, are size exclusion 
chromatography (SEC) columns and membrane ultrafiltration. SEC purification resulted in 
pure EV fractions (Boing et al., 2014) whereas ultrafiltration often results in co-isolation of 
macromolecular aggregates that stick to the membranes (Abramowicz et al., 2016). In 
addition, EVs can be isolated by using immunocapture approaches such as magnetic beads 
coupled to a specific antibody that recognizes a surface marker protein of EVs (Shi et al., 
2014).  
Within this study, the term exosomes is used to describe EVs with the size of 40 – 100 nm 





Biomarkers (biological markers) are basically defined as indicators of biological conditions 
including healthy and pathological processes (Hulka and Wilcosky, 1988). They are 
measurable in tissues and body fluids and a reliable biomarker is characterized by its 
accurate, reproducible and robust quantification. Multiple molecules including proteins, 
metabolites, DNA and RNA species are used as biomarkers to facilitate diagnosis and 
prognosis of a current disease (Boukouris and Mathivanan, 2015). The identification and 
validation of circulating biomarkers in body fluids, such as blood (plasma and serum), urine, 
saliva and CSF raised immense attention due to the non-invasive and quick sample drawing, 
thus enabling early diagnosis and therapy.  
Pathophysiological changes including protein misfolding, aggregation and further loss of 
neuronal function and integrity are processes which start years before the first clinical 
symptoms of neurodegeneration arise. Currently, pharmacological treatment is only 
symptomatic and no treatment exists that prevents these diseases or influences their 
progression. Further, accurate diagnosis of a specific disease is often hampered due to an 
overlap of clinical symptoms and neuropathological changes. These obstacles point out that 
there is a strong need for reliable biomarkers to predict and diagnose disorders in a 
preclinical stage in order to target and/or monitor early changes in the brain when they are 
potentially reversible.  
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1.2.1. Alzheimer`s disease 
AD is the most common neurodegenerative disorder and the main cause of dementia 
worldwide (Blennow et al., 2006). Epidemiological studies have estimated that 40 million 
persons over 60 years are living with dementia and this is expected to double every 20 years 
(Scheltens et al., 2016). Clinically, AD is characterized by a progressive loss of cognitive 
function and daily-life activities.  
Onset of clinical symptoms is preceded by a preclinical stage, which may start decades 
earlier (Jack and Holtzman, 2013). Mild cognitive impairment (MCI) is a possible prodromal 
stage with subtle cognitive symptoms, which do not fulfill the criteria of dementia (Petersen, 
2004; Winblad et al., 2004). MCI patients have an increased probability of progression 
towards AD, which depends further on the presence or absence of biomarkers indicative of 
AD pathology (Albert et al., 2011). Despite the availability of biomarkers such as CSF Aβ, CSF 
Tau and amyloid positron emission tomography (PET) imaging, there is still a risk of false 
positive or false negative test results (Coart et al., 2015). Predictive testing has far-reaching 
consequences, especially in light of the notion that any disease-modifying therapy should 
start in the earliest possible disease stage (Cummings et al., 2007). However, better markers 
are needed to unequivocally identify those patients which MCI who will later progress to AD. 
 
1.2.2. Parkinson`s disease and dementia with Lewy bodies 
PD is the second most common neurodegenerative disorder that affects 1 – 2% of the 
population older than 65 years (Goedert, 2001). It is a progressive disorder characterized by 
the specific loss of midbrain dopaminergic neurons in the substantia nigra and the presence 
of intracellular protein deposits named Lewy bodies which predominantly consist of 
pathologically aggregated α-Synuclein (Spillantini et al., 1998). The core clinical symptoms 
include bradykinesia, tremor in rest and rigidity that is often accompanied by postural 
instabilities in later disease stages (Jankovic, 2008; Postuma et al., 2015). In addition, non-
motor symptoms such as autonomic dysfunction, hyposmia, sleep disturbances and 
psychiatric disorders e.g. depression are present in many patients. 
While 90% of PD patients are sporadically diseased (de Lau and Breteler, 2006), a small 
portion belongs to the familiar form which is usually characterized by an earlier disease 
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onset. Genetic studies have identified mutations in several genes encoding for proteins 
linked to PD including α-Synuclein (Kruger et al., 1998; Polymeropoulos et al., 1997), Parkin 
(Kitada et al., 1998)or DJ-1 (Bonifati et al., 2003). 
DLB is characterized by Lewy bodies which, in contrast to PD, are also present in higher 
cortical regions (Kosaka, 1990). The disease is clinically defined by Parkinson syndrome plus 
cognitive impairment, fluctuating attention, visual hallucinations and often sleep 
disturbances within one year of onset of Parkinson syndrome (McKeith et al., 2005). A high 
proportion of PD patients also develop cognitive impairment during the disease progression 
which can result in a difficult differential diagnosis between both diseases (Fahn, 2003), even 
among specialized motor centers. 
Similar to AD, PD and DLB are characterized by a preclinical phase in which 
neuropathological changes occur in the absence of clinical symtoms. At clinical disease 
onset, already 60 – 70% of the dopaminergic neurons are lost in PD (Lang and Lozano, 1998). 
As in AD, a disease modifying therapy is not yet available but there is a broad consensus that 
such a therapy would need to start as early as possible, ideally in the preclinical stage. 
 
1.2.2.1. CSF biomarkers 
CSF represents a nearly optimal source of neurodegenerative disease biomarkers due to its 
close proximity to the extracellular space of the brain, thus providing potential conditions to 
reflect and track biochemical changes in the brain. In AD, CSF biomarkers already found their 
way into clinical practice, whereas CSF biomarkers in PD and α-Synuclein pathology related 
diseases are currently restricted to clinical studies and trials (Lleo et al., 2015). 
Several studies evaluated the potential of extracellular α-Synuclein in CSF as a diagnostic 
biomarker in PD and other synucleinopathies, such as DLB. Most studies reported reduced 
CSF total α-Synuclein levels of patients with PD and DLB compared to AD patients or 
neurological controls (Mollenhauer et al., 2011; Parnetti et al., 2011; Tokuda et al., 2006). 
However, CSF total α-Synuclein levels of PD and DLB patients were found to overlap with 
those levels of patient groups suffering from non α-Synuclein related Parkinson syndrome 
(Aerts et al., 2012). In addition, several studies have detected similar α-Synuclein 
concentrations when comparing DLB patients with other dementias as AD or frontotemporal 
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dementia (Noguchi-Shinohara et al., 2009; Reesink et al., 2010; Spies et al., 2009). Thus, 
extracellular (CSF) α-Synuclein has not been approved as a biomarker for clinical use (Gao et 
al., 2015). 
 
1.2.2.2. Plasma biomarkers 
Blood based biomarkers are highly attractive since blood is easy to obtain and allows follow-
up investigations in long-term studies to track the course of the disease. Regarding 
synucleinopathies, α-Synuclein levels were predominantly examined in plasma samples with 
variable results. α-Synuclein levels were found to be increased in plasma derived from PD 
patients compared to controls (Duran et al., 2010; Lee et al., 2006) as were α-Synuclein 
oligomers (El-Agnaf et al., 2006). In another study, α-Synuclein levels were decreased in PD 
patients compared to controls (Li et al., 2007). Interestingly, α-Synuclein was also lower in 
PD plasma after the inhibition of heterophilic antibodies, which are present in human blood 
and might produce false positive signals due to their potential binding to the antibodies used 
in α-Synuclein ELISAs (Ishii et al., 2015). Furthermore, overlapping α-Synuclein levels were 
reported in plasma of PD, AD and control samples (Shi et al., 2010).  
Overall, extracellular α-Synuclein has not been approved as a biomarker in human body 
fluids and a neurochemical biomarker of disease state and trait in PD is missing. 
 
1.2.3. Small ncRNAs as potential biomarkers in neurodegenerative diseases 
The human genome project revealed that protein-coding sequences only represent 
approximately 1.5% of the entire genome (Lander et al., 2001) with a huge portion of the 
genome being transcribed into non-coding RNAs (ncRNAs). These RNA species comprise a 
class of regulatory small/short RNAs with up to 200 nucleotides (Kapranov et al., 2007), 
which is further divided into miRNA, small interfering RNA (siRNA), snRNA, snoRNA, piRNA, 
tRNA and ribosomal RNA (rRNA) (Huttenhofer et al., 2005).  
The best characterized small ncRNAs are represented by the members of the miRNA family, 
which are approximately 22 nucleotides long. miRNAs regulate gene expression post-
transcriptionally either by cleaving their target mRNA followed by further degradation or by 
blocking protein translation. The biogenesis of miRNAs is a complex multistep process that 
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involes the RNAse enzymes Drosha and Dicer, which are responsible for the processing of 
long primary miRNAs to premature miRNAs and further into mature miRNA molecules, 
respectively. The mature miRNA is then loaded into the RNA-induced silencing complex 
(RISC) which then recognizes and binds to a complementary sequence in the target mRNA 
(Esteller, 2011). 
Besides their physiological regulatory functions on proliferation, differentiation, 
development and apoptotic processes (Esteller, 2011), miRNAs seem to be involved in 
multiple diseases where their expression level is often significantly altered. miRNAs were 
found to be highly abundant in the CNS and dysregulated miRNA expression was observed in 
specific brain regions of patients with neurodegenerative disorders including PD (Alvarez-
Erviti et al., 2013; Cardo et al., 2014; Kim and Kim, 2007) and AD (Geekiyanage and Chan, 
2011; Shioya et al., 2010; Smith et al., 2011). Hence, disease specific miRNA expression 
pattern were proposed to provide important information regarding disease diagnosis and 
progression. Extracellular miRNAs circulate in body fluids and are characterized by a high 
stability with relatively slow turnover rates (Zhang et al., 2012), thus raising the possibility to 
use them as biomarkers. 
Patient fluids have been screened to identifiy specific miRNA signatures by using different 
techniques such as microarray, NGS or real-time PCR. Several studies investigated whole 
blood-, plasma-, serum- and CSF-based miRNAs in PD patients (Burgos et al., 2014; Cardo et 
al., 2013; Khoo et al., 2012; Margis and Rieder, 2011; Vallelunga et al., 2014) as well as in AD 
patients (Cogswell et al., 2008; Kumar et al., 2013; Leidinger et al., 2013). All of them found 
dysregulated expression levels of several miRNAs with putative target genes involved in PD 
and AD, nevertheless analyses also resulted in diverging miRNA profiles even for the same 
disease.  
In addition, miRNA signatures in body fluids did not correlate well with those found in brain 
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1.2.3.1. Exosomal small ncRNAs as potential biomarkers 
Exosomes are detectable in body fluids and contain specific cargo molecules, such as 
proteins and RNA. Thus, they bear the potential to be used as diagnostic and prognostic 
biomarkers in various diseases including neurodegenerative disorders (Vella et al., 2016). 
Exosomes provide a protective envelope for their cargo, such as RNA (Cheng et al., 2014a). 
NGS of exosomal RNA released from prion-infected neuronal mouse cells revealed 
differentially expressed miRNAs compared to exosomes from non-infected cells (Bellingham 
et al., 2012a). Moreover, the diagnostic potential of a serum exosomal miRNA expression 
pattern was tested and could differentiate AD patients from controls in serum of AD patients 
(Cheng et al., 2015). Recently, Gui et al. (2015) identified altered miRNA expression levels in 
CSF exosomes from patients with PD compared to controls by using microarray analysis.  
These studies strongly suggest that exosomal RNA may be suitable to discriminate between 
diseased patients and healthy controls and other neurodegenerative diseases. However, as 
for free extracellular small ncRNA, the diagnostic signatures identified by different studies 




α-Synuclein is an intracellular soluble protein of 140 amino acids and member of the 
Synuclein family which additionally comprises β-Synuclein and γ-Synuclein. All Synuclein 
proteins are abundantly expressed in the brain (George, 2002). 
 
1.3.1. Structure and function 
α-Synuclein contains an amphipathic N-terminal region with a conserved repeat sequence 
that was shown to bind to phospholipids (Perrin et al., 2000) followed by a highly 
hydrophobic domain which was suggested to be sufficient for α-Synuclein aggregation and 
fibril formation (Bodles et al., 2001; Giasson et al., 2001). C-terminal truncated α-Synuclein 
was shown to seed and facilitate the aggregation of full-length α-Synuclein in vitro (Murray 
et al., 2003).  
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In solution, α-Synuclein is a native unfolded protein (Weinreb et al., 1996), however it was 
found to be stabilized in an α-helical conformation upon binding to lipid membranes 
(Davidson et al., 1998; Eliezer et al., 2001; Jo et al., 2000). It has been suggested that 
endogenous α-Synuclein could occur natively as a helical folded tetramer that resists 
aggregation and co-exists in equilibrium with unfolded monomers (Bartels et al., 2011; 
Dettmer et al., 2015). However, the natively tetrameric structure seems to be controversial 
since α-Synuclein purified from mouse and human brains was reported to predominantly 
consists of unfolded monomers (Burre et al., 2013; Fauvet et al., 2012). 
α-Synuclein is primaly localized to the synapse (Iwai et al., 1995) and was found in 
association to synaptic vesicles (Maroteaux and Scheller, 1991). Evidence from several 
studies suggests that α-Synuclein plays a role in synaptic transmission through influence on 
the synaptic vesicle cycle including vesicle endocytosis, recycling and exocytosis (Lundblad et 
al., 2012; Scott and Roy, 2012; Vargas et al., 2014). α-Synuclein overexpression leads to 
decreased neurotransmitter release (Lundblad et al., 2012; Nemani et al., 2010) and the size 
of the vesicle recycling pool is reduced (Nemani et al., 2010) whereas an absence of 
α-Synuclein results in larger recycling pools and enhanced synaptic trafficking (Scott and Roy, 
2012). These results indicate that α-Synuclein might be a potential negative regulator of 
synaptic transmission. 
 
1.3.2. α-Synuclein pathology  
The pathological relevance of α-Synuclein became evident when different missense 
mutations in, or triplicates of the α-Synuclein gene were found to cause familiar PD (Kruger 
et al., 1998; Polymeropoulos et al., 1997; Singleton et al., 2003; Zarranz et al., 2004). 
Multiple animal models (e.g. transgenic mouse and fly models) further supported the 
pathogenic role of α-Synuclein in PD (Benskey et al., 2016). α-Synuclein represents the major 
component of LBs (Spillantini et al., 1997) which are found to spread in a topographical 
pattern in the brain during disease course (Brettschneider et al., 2015). 
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1.4. Aims of the study 
1.4.1. Characterization of CSF and plasma exosomal α-Synuclein in PD and DLB 
patients 
Based on the finding that extracellular α-Synuclein exists in vivo where it is partially localized 
in exosomes and that exosomes might contribute to the dissemination of aberrant proteins 
in neurodegenerative diseases, we characterized exosomal α-Synuclein purified from CSF 
and plasma of patients with α-Synuclein related neurodegeneration (PD and DLB), patients 
with no α-Synuclein related Parkinson syndrome (progressive supranuclear palsy, PSP) and 
neurological controls with no indication of neurodegeneration. The present study includes 
the quantification of exosome numbers as well as exosomal α-Synuclein levels in all patient 
groups and the first evaluation of CSF exosomal α-Synuclein to serve as a biomarker for 
differential diagnostic purpose. Furthermore, the impact of CSF exosomes from these 
diagnostic groups on the aggregation of soluble α-Synuclein was investigated in a reporter 
cell assay. 
 
1.4.2. CSF exosomal small ncRNAs as a biomarker for AD 
The aim of the second study was to analyze the exososomal small ncRNA composition of 
exosomes prepared from human CSF and determine whether CSF exosomal small ncRNA 
profiles may distinguish AD from cognitively healthy controls. In particular, our study 
investigated (a) whether exosomal small ncRNAs reflect neuronal small ncRNA composition 
and (b) whether these profiles can be used as a diagnostic biomarker to distinguish between 
AD and controls. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals and consumables 
Unless indicated otherwise, chemicals were purchased from AppliChem GmbH (Darmstadt, 
Germany), Merck KGaA (Darmstadt, Germany) or Sigma-Aldrich Chemie GmbH (Munich, 
Germany). Plastic consumables were purchased from BD Falcon™ (BD Biosciences, Le Pont 
de Claix, France), Greiner bio-One GmbH (Frickenhausen, Germany), Starlab GmbH 
(Hamburg, Germany), and Eppendorf AG (Hamburg, Germany). 
 
2.1.2. Antibodies 
Primary antibodies are listed in Table 2.1. Horseradish peroxidase (HRP) conjugated 
secondary antibodies against mouse, rabbit, and human Immunoglobulin G (IgG) were 
obtained from Dako (Hamburg, Germany), Dianova GmbH (Hamburg, Germany), and 
Invitrogen (Thermo Fisher Scientific, Waltham, MA, USA). 
Table 2.1: List of primary antibodies 
Antibody Host species Company, catalog number Dilution 
Anti-Flotillin-2 mouse BD Biosciences, 610384 1:1000 (WB) 
Anti-Calnexin rabbit Sigma-Aldrich, C4731 1:1000 (WB) 
Anti-α-Synuclein clone  
Syn 211 
mouse Invitrogen, 32-8100 1:1000 (WB) 
Anti-α-Synuclein clone 
42/α-Synuclein 
mouse BD Biosciences, 610787 1:250 (ECL assay) 
Anti-α-Synuclein MJF-1 
clone 12.1 
rabbit kindly provided by Dr. Liyu Wu 
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2.1.3. Plasmids 
α-Synuclein-hGLuc1 (S1) and α-Synuclein-hGLuc2 (S2) plasmids were described in Outeiro et 
al. (2008). In short, α-Synuclein was subcloned into the Not1/Cla1 sites of constructs 
containing specific fragments of humanized Gaussia Luciferase (kindly provided by Dr. 
Stephen Michnick, University of Montreal) to generate α-Synuclein-hGLuc1 (S1) and 
α-Synuclein-hGLuc2 (S2) fusion constructs. Construct S1 contains the N-terminal fragment of 
hGLuc (aa 1 – 93) and S2 contains the C-terminal fragment of hGLuc (aa 94 – 185). 
 
2.1.4. Buffer and solutions 
Phosphate buffered saline (PBS) 
10x stock solution 
1.37 M NaCl 
27 mM KCl 
100 mM Na2HPO4 
18 mM KH2PO4 
The final volume was filled up to 1 liter with dH2O and the pH was adjusted to 7.4 
 
PBS-Citrate 0.32% 
PBS was prepared as decribed above and diluted to 1x PBS solution in dH2O. 0.32% 
Trisodium citrate (w/v) was then added and the pH was adjusted to 7.4 followed by filtration 
through a 0.22 µm filter.  
 
PBS-0.05% or 0.025% Tween-20 (PBST) 
PBS was prepared as decribed above and diluted to 1x PBS solution in dH2O. 0.05% or 
0.025% Tween-20 (MP Biomedicals LLC; Santa Ana, CA, USA) was added and the solution was 




2. Materials and Methods| 22 
 
Tris buffered saline (TBS) 
10x stock solution 
1.37 M NaCl 
27 mM KCl 
248 mM Tris base 
The final volume was filled up to 1 liter with dH2O and the pH was adjusted to 7.4 
 
CHAPS lysis buffer  
10% stock solution 
10% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) 
5 mM EDTA (Ethylenediaminetetraacetic acid) 
50 mM Tris-HCl [Tris(hydroxymethyl)aminomethane] 
The pH was adjusted to 8.0. To obtain 1% or 2% CHAPS lysis buffer, 10% stock solution was 
further diluted in 50 mM Tris-HCl/5 mM EDTA. 
 
Protein loading buffer 
5x loading buffer 
312.5 mM Tris-HCl, pH 6.8 
5 mM EDTA, pH 8.0 
10% (w/v) Sodium dodecyl sulfate (SDS) 
0.05% (w/v) Bromphenol Blue 




2. Materials and Methods| 23 
 
2.1.5. Commercial solutions, media and components 
Commercial available solutions, media and components used during this study are listed in 
Table 2.2. 
Table 2.2: Commercial solutions, media and components 
Solution/Medium Company 
cOmplete™ Protease inhibitor cocktail Roche Diagnostics, Rotkreuz, Switzerland 
Dulbecco`s Modified Eagle Medium (DMEM) Gibco®, Thermo Fisher Scientific, Waltham, MA, USA 
Fetal Calf Serum (FCS) GE Healthcare Life Sciences, Little Chalfont, United 
Kingdom and Gibco®, Thermo Fisher Scientific, 
Waltham, MA, USA 
GlutaMAX™ Gibco®, Thermo Fisher Scientific, Waltham, MA, USA 
Hank`s buffered saline solution (HBSS) Gibco®, Thermo Fisher Scientific, Waltham, MA, USA 
Minimum essential medium (MEM) Gibco®, Thermo Fisher Scientific, Waltham, MA, USA 
Opti-MEM® I reduced serum Gibco®, Thermo Fisher Scientific, Waltham, MA, USA 
PBS Gibco®, Thermo Fisher Scientific, Waltham, MA, USA 
Penicillin/Streptomycin (Pen/Strep), 100 x Gibco®, Thermo Fisher Scientific, Waltham, MA, USA 
SuperFect® transfection reagent  Qiagen GmbH, Hilden, Germany 
Trypsin-EDTA, 0.25% Gibco®, Thermo Fisher Scientific, Waltham, MA, USA 
 
2.1.6. Commercial kits 
Table 2.3 depicts commercial kits used in this study. 
Table 2.3: Commercial kits 
Kit Application Company 
Agilent RNA 6000 Pico Kit RNA quality and quantity Agilent Technologies, Santa 
Clara, CA, USA 
INNOTEST® hTAU Ag ELISA Kit  Detection of Tau protein in 
human CSF 
Innogenetics N.V., Ghent, 
Belgium 
TruSeq Small RNA Library 
Preparation Kit 
Small RNA library preparation Illumina Inc., San Diego, CA, USA 
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2.1.7. Software 
The software used in this sudy are stated in Table 2.4 
Table 2.4: Software 
Software Application Source 
Adobe Illustrator CS5.1  Illustration of figures Adobe Systems Inc. 
EndNote X5 Bibliography managing Thomson Reuters 
GraphPad Prism® 6 Statistical analysis and graph 
illustration 
GraphPad Software Inc. 
MS Office Excel 2010 Statistical analysis and graph 
illustration 
Microsoft 
MS Office Word 2010 Text writing and editing Microsoft 
NanoSight Tracking Analysis 2.3 Number and concentration of 
exosomes in liquids 
Malvern Instruments 




2.2.1. Patient material 
2.2.1.1. Cerebrospinal fluid collection 
CSF samples were obtained from the Paracelsus-Elena Klinik Kassel, Germany and the 
Memory Clinic of the University Medical Center Göttingen, Department of Psychiatry, 
Germany after written informed consent was given by the participants. The use of CSF 
samples was approved by the Institutional review board (IRB) of the local board of Hessen, 
Germany (IRB 09/07/04 and 26/07/02) and the Ethics committee of the University Medical 
Center Göttingen (IRB 02/05/09). Samples used in this study were collected between 2009 
and 2012 in polypropylene tubes by lumbar puncture between 9 and 12 a.m. followed by 
centrifugation at 2000 x g for 10 minutes (min) at room temperature (RT). The CSF 
supernatant was aliquoted and flash frozen at −80°C within 30 min of completion of the 
procedure. Samples with erythrocyte counts > 50/mm3 were excluded from the study. All 
samples were obtained according to the ethical principles as defined in the Declaration of 
Helsinki (1964). 
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2.2.1.2. Plasma collection  
Plasma samples were also obtained from the Paracelsus-Elena Klinik Kassel (IRB 09/07/04 
and 26/07/02) and the Memory Clinic of the University Medical Center Göttingen, 
Department of Psychiatry (IRB 02/05/09), Germany. After written informed consent was 
given by the participants blood was drawn and collected in plasma monovettes supplied 
with lithium heparin. Samples were centrifuged at 2000 x g for 10 min at RT within 1 hour 
after blood draw. The supernatant was then aliquoted and immediately stored at −80°C until 
further use.  
 
2.2.2. Patient cohorts 
2.2.2.1. The cross-sectional Kassel cohort 
The cross-sectional Kassel cohort comprises patients suffering from multiple neurological 
disorders including DLB, PD and PSP and is described in detail in Mollenhauer et al. (2011). 
DLB was clinically diagnosed in accordance with the McKeith consensus criteria (McKeith et 
al., 2005). All patients diagnosed with PD fulfilled UK Brain Bank criteria and patients with 
PSP fulfilled the National Institute of Neurological Disorders and Stroke Society for 
Progressive Supranuclear Palsy (NINDS-SPSP) criteria for possible or probable disease (Litvan 
et al., 1996). None of the neurological control patients who were selected from the cohort 
suffered from PD or dementia. For this study, CSF and plasma samples were obtained from 
the Kassel cohort. Demographic information of the analyzed samples is given in Table 6.2 for 
CSF and in Table 6.3 for plasma samples. 
 
2.2.2.2. The DeNoPa cohort 
The longitudinal de novo Parkinson (DeNoPa) cohort consists of 159 PD patients who have 
been diagnosed according to the UK Brain Bank criteria and were drug naïve at enrollment. 
In addition, 150 neurologically healthy controls matching for age, gender and educational 
levels were included in the study in parallel. Controls had no family history of PD. Study 
enrollment was completed between 9/2009 and 1/2012 and the cohort will be followed for 
several years with follow-up investigations every two years. 94% of participants returned for 
2. Materials and Methods| 26 
 
the first follow-up and clinical baseline diagnosis was confirmed in 84%. CSF was obtained by 
lumbar puncture between 8 and 9 a.m. and collected in polypropylene tubes followed by 
further processing (centrifugation and freezing) within 30 min according to a protocol from 
Mollenhauer et al. (2010). For this study, 76 patients with PD and 58 healthy controls who 
had completed their first follow-up with normal routine CSF parameters including 
haemoglobin and protein content, were randomly chosen from the DeNoPa cohort. 
Demographic information of the analyzed CSF samples is displayed in Table 6.1. 
 
2.2.2.3. Cohorts for small ncRNA sequencing  
The test cohort 
Samples of the CSF test cohort used for small ncRNA sequencing were obtained from the 
University Medical Center Göttingen and collected between 2012 and 2013. The cohort 
comprises 24 AD patients who have been diagnosed according to the criteria of the National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer`s 
disease and related Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984) after 
clinical assessment including neuropsychological testing, neurological examination and CSF 
parameter diagnostics. In addition, 18 control samples, which were provided by the 
Department of Psychiatry, Göttingen were included. None of the control patients suffered 
from dementia or neurodegeneration. Further demographic information of the used 
samples is specified in Table 6.4. 
The replication cohort 
The replication cohort comprises 21 patients diagnosed with AD and 20 control patients. 19 
AD samples were collected in Göttingen (identical to the test cohort) and 2 AD samples were 
collected at the Department of Neurology, University Hospital Tübingen. The control 
samples were obtained from three different centers including Göttingen (10 samples), 
Tübingen (2 samples) and the Paracelsus-Elena Klinik Kassel (6 samples). Collection, storage 
and processing of the samples were performed by using the same protocol. Further 
demographic information of the analyzed samples is given in Table 6.5. 
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2.2.3. Purification of exosomes from CSF and plasma 
Exosomes were purified from frozen CSF or plasma samples (see also section 2.2.1.1 and 
2.2.1.2). 
2.2.3.1. Purification of exosomes by ultracentrifugation 
Exosome isolation from CSF or plasma was performed according to a protocol from Strauss 
et al. (2010). CSF or plasma was thawed on ice and subjected to serial centrifugation steps at 
4°C with the supernatant collected and the pellet discarded each time: 3,500 x g for 10 min, 
two times 4,500 x g for 10 min and 10,000 x g for 30 min. The supernatant was finally 
subjected to UC at 100,000 x g for 60 min to obtain the exosome pellet. The pellet was 
washed once with PBS at 100,000 x g for 60 min followed by resuspension in appropriate 
buffers or solutions.  
For Western blot (WB) analysis, exosomes were prepared from 2.5 ml CSF and resuspended 
in 5x protein loading buffer (for protocol, see section 2.1.4). For α-Synuclein measurements, 
exosomes were prepared from 500 µl CSF or plasma and dissolved in 50 µl 1% CHAPS lysis 
buffer (see 2.1.4 for protocol). Exosomes for the Gaussia luciferase protein-fragment 
complementation assay were purified from CSF under sterile conditions and dissolved in 
50 µl PBS for further use. For exosomal RNA isolation, exosomes were purified from 500 µl 
CSF and resuspended in 200 µl TRI Reagent®. Samples were then stored at −80°C until RNA 
extraction was performed (section 2.2.8). 
 
2.2.3.2. Purification of plasma exosomes by Size Exclusion Chromatography (SEC) 
In addition to the UC based isolation method, exosomes from 1 ml plasma were purified by 
single-step SEC. This method is based on vesicle separation by size and was used for the 
isolation of EVs from body fluids as described previously (Boing et al., 2014; Muller et al., 
2014). Plasma samples were processed according to the serial centrifugation protocol at 4°C 
(see also 2.2.3.1): one time 3,500 x g, two times 4,500 x g (10 min each) and one time 
10,000 x g for 30 min centrifugation steps were performed before SEC. The supernatant was 
immediately applied to a commercial qEV column (Izon Science Limited, Cambridge, MA, 
USA) that was equilibrated with 10 ml of PBS containing 0.32% Trisodium citrate (PBS-
Citrate, pH 7.4) before, in accordance to the protocol from Boing et al. (2014).  
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Subsequently, the applied sample was eluted with PBS-Citrate and 24 fractions of 500 µl 
were collected followed by washing of the column with at least 30 ml PBS before reuse. All 
SEC steps were carried out at RT and 0.22 µm filtered buffers were used. 
For each fraction, the number of particles was measured by nanoparticle tracking analysis 
(NTA, section 2.2.4.1). Fractions containing the highest concentrations of particles were 
pooled as the exosome fraction and concentrated to 90 µl by centrifugation at 4,000 x g and 
4°C in an Amicon Ultra centrifugal filter with a 3 kD cut-off (Merck Millipore, Darmstadt, 
Germany). 10 µl of 10% CHAPS lysis buffer were added and samples were stored at −20°C 
until α-Synuclein quantification (see 2.2.6.3). For WB analysis, SEC fractions were diluted 
1:100 in PBS and supplied with 5x protein loading buffer. 
 
2.2.4. Analysis of exosomes 
2.2.4.1. Nanoparticle tracking analysis (NTA) 
The NTA technique allows rapid measurements of size distribution and concentration of 
vesicles in solution (Dragovic et al., 2011). Here, particles are illuminated by laser light and 
their individual movement is tracked followed by the determination of each vesicle`s 
diameter based on Bronian motion. Concentration and size distribution of particles in CSF 
and plasma were analyzed with a NanoSight LM10-HS instrument equipped with a high 
sensitivity CMOS camera and a LM14 viewing unit comprising a 532 nm laser (NanoSight, 
part of Malvern Instruments Ltd, Malvern, UK). 
Exosomes in unprocessed fractions or in the UC preparation from CSF as well as exosomes in 
SEC derived plasma fractions were analyzed in appropriate dilutions to keep the particles in 
the field of view below 100 per image. More specific, total CSF samples were diluted 1:4 to 
1:40 in PBS and total plasma samples were diluted 1:10,000 in PBST-0.025% prior to analysis. 
UC pellets derived from 500 µl CSF were resuspended in 50 µl PBS and diluted 1:40 in PBS. 
SEC fractions derived from 1 ml plasma were diluted 1:800 in PBST-0.025%. Samples were 
applied to the laser chamber by using a syringe and 30 sec videos were taken under 
automated settings. Samples were recorded in triplicates (DeNoPa cohort) or six times (all 
other samples). Particle numbers and size distribution were then automatically analyzed 
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with the NanoSight Tracking Analysis 2.3 software. A minimum of 200 tracks per video was 
analyzed and a cut-off at 120 nm was used for the quantification of exosome numbers. 
 
2.2.4.2. Electron microscopy (EM) 
Exosomes were prepared from 4 ml CSF as described in section 2.2.3.1 followed by fixation 
of the 100,000 x g pellet in 4% Paraformaldehyde (PFA). Then, exosomes were layered onto 
glow discharged Formvar-carbon-coated copper grids and the grids were negatively stained 
with 2% uranyl acetate containing 0.7 M oxalate, pH 7.0. Imaging was performed with a LEO 
EM912 Omega electron microscope (Carl Zeiss, Oberkochen, Germany) and digital 
micrographs were captured with an on-axis 2048 x 2048 pixel CCD camera (Proscan Special 
Instruments Ltd., Minsk, Belarus). 
EM of CSF exosomes was kindly performed by Dr. Wiebke Möbius (MPI of Experimental 
Medicine, Göttingen). 
 
2.2.5. Cell culture 
2.2.5.1. Maintenance of cell lines 
Cells were grown at 37°C and 5% CO2 in humidified incubators in 75 cm
2 cell culture flasks or 
10 cm petri dishes (both obtained from BD), respectively. 
Mouse neuroblastoma N2a cells were maintained in Dulbecco`s Modified Eagle Medium 
(DMEM; Gibco®, Thermo Fisher Scientific, Waltham, MA, USA ) containing 4.5 g/L glucose 
and supplemented with 10% fetal calf serum (FCS; GE Healthcare Life Sciences, Little 
Chalfont, United Kingdom), 1% GlutaMAX™ and 1% Penicillin/Streptomycin (both from 
Gibco®, Thermo Fisher Scientific, Waltham, MA, USA). 
Human neuroglioma H4 cells (Cell Lines Service GmbH, Eppelheim, Germany) were 
maintained in Opti-MEM® I reduced serum medium supplemented with 10% FCS (both from 
Gibco®, Thermo Fisher Scientific, Waltham, MA, USA). 
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2.2.5.2. Transfection of H4 cells and treatment with CSF derived exosomes 
H4 cells were plated on 96 well plates 24 hours prior to transfection which was performed at 
80 – 90% cell confluency using SuperFect® transfection reagent (Qiagen GmbH, Hilden, 
Germany). Cells were transiently transfected with equimolar ratios of the plasmids 
α-Synuclein-hGLuc1 (S1) and α-Synuclein-hGLuc2 (S2, see also 2.1.3) according to the 
manufacturer`s instructions. After 2 hours of incubation under normal growth conditions the 
transfection mix was removed from the cells and fresh Opti-MEM® medium supplemented 
with 10% FCS containing purified CSF exosomes derived from DLB patients, PD patients and 
neurological control patients was added. After 12 hours the split-luciferase protein fragment 
complementation assay was performed to measure the aggregation of α-Synuclein in the 
cells as described in section 2.2.6.5. 
Transfection of H4 cells, treatment with purified CSF exosomes and the split-luciferase 
protein fragment complementation assay were kindly performed by the group of Prof. Dr. 
Karin Danzer (Department of Neurology, Ulm University). 
 
2.2.5.3. Primary mouse cortical and hippocampal neuronal cultures 
Primary cell cultures were generated from the cerebral cortex or hippocampus of mouse 
embryos at embryonic day 16.5. To this end, a pregnant NMRI mouse was sacrificed and 
embryos were removed immediately from the amniotic sac. Cortices or hippocampi were 
then dissected and collected in sterile Hank`s buffered saline solution (HBSS; Gibco®, Thermo 
Fisher Scientific, Waltham, MA, USA ) at RT. After transferring hippocampal or cortical tissue 
from all embryos into a sterile tube, 500 µl of 0.05% Trypsin-EDTA was added and the 
mixture was incubated for 10 min at 37°C in the incubator. Trypsination was then stopped 
with DMEM supplemented with 10% FCS, 1% GlutaMAX™ and 1% Penicillin/Streptomycin. To 
obtain a single cell suspension, the mixture was homogenized by resuspending with a glass 
pipette. 1 ml of growth medium MEM-B27 [Minimum essential medium (MEM) with 0.2% 
sodium bicarbonate solution, 0.6% glucose, 1% sodium pyruvate (100x), 1% 
Penicillin/Streptomycin, 1% GlutaMAX™ and 2% B27 supplement 50x (all obtained from 
Gibco®, Thermo Fisher Scientific, Waltham, MA, USA)] was added per brain followed by the 
filtration of the cell suspension through a cell strainer (BD Falcon™). 30 µl cell suspension 
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was plated in each well of a 12 well plate precoated with poly-L-lysine and cultures were 
grown for up to 2 weeks in 1 ml growth medium MEM-B27 per well. 
One day before exosome purification, the growth medium was changed to 500 µl medium 
and exosomes were collected for 16 hours. For exosome isolation, the medium was removed 
from the cells and subjected to UC purification as described in section 2.2.3.1. Cells were 
washed once with PBS before scraping them in 200 µl TRI Reagent®. Cell lysates were then 
stored at −80°C until further processing for RNA extraction (see section 2.2.8).  
 
2.2.6. Protein biochemistry 
2.2.6.1. Preparation of cell lysates for protein analysis 
For protein analysis, N2a cells were cultured in 10 cm petri dishes for at least 24 hours and 
scraped in 400 µl 1% CHAPS lysis buffer supplemented with cOmplete™ Protease inhibitor 
cocktail 1:25 (Roche Diagnostics, Rotkreuz, Switzerland). Cell lysates were centrifuged at 
4,500 x g for 10 min at 4°C to remove cellular debris and 400 µl supernatant was diluted with 
160 µl 5x protein loading buffer for western blot analysis. 
 
2.2.6.2. Western Blot Analysis 
Protein detection by WB analysis was performed to detect Flotillin-2 in CSF exosomes, 
Calnexin in total CSF and IgG in total plasma. 
SDS-PAGE 
Proteins of CSF exosomes, total CSF and N2a cell lysates were separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970) under denaturating 
conditions by using the Bio-Rad Mini-PROTEAN® Tetra electrophoresis system (Bio-Rad 
Laboratories GmbH, Munich, Germany). 12% resolving gels and 4% stacking gels were 




2. Materials and Methods| 32 
 
Table 2.5: Composition of stacking and resolving gel for SDS-PAGE 
Stacking gel (4%) Resolving gel (12%) 
4% Acrylamide/Bis Solution 30% 
(37.5:1)  
12% Acrylamide/Bis Solution 30% 
(37.5:1) 
125 mM Tris-HCl pH 6.8 375 mM Tris-HCl pH 8.8 
0.1%  SDS 0.1% SDS 





UC purified CSF exosomes were resuspended in 20 µl 5x protein sample buffer, UC plasma 
exosomes and plasma SEC fractions were diluted 1:100 prior adding protein sample buffer 
and total CSF/plasma and N2a cell lysates were diluted 1:5 in protein sample buffer followed 
by incubation at 95°C for 5 min. 20 µl of UC CSF/plasma exosomes, total CSF/plasma or N2a 
cell lysate and 15 µl of plasma SEC fractions were loaded on the gel together with 3 µl of the 
protein marker PageRuler™ Plus Prestained Protein Ladder (Thermo Fisher Scientific, 
Waltham, MA, USA). Electrophoresis was performed in one time running buffer (25 mM Tris, 
190 mM Glycine, 0.1% SDS) at 100 V for 120 min.  
Protein transfer to membrane and immunodetection of proteins 
Proteins were transferred from the gel onto an Amersham™ Protran™ nitrocellulose 
membrane (GE Healthcare Life Sciences, Little Chalfont, United Kingdom) by using the Mini 
Trans-Blot® tank blot system (Bio-Rad Laboratories GmbH, Munich, Germany). Blotting was 
performed at 100 V for 55 min in one time transfer buffer (25 mM Tris, 190 mM Glycine, 
20% Methanol). After protein transfer, the nitrocellulose membrane was treated with 
Ponceau S solution [0.1% (w/v) Ponceau S in 5% (v/v) acetic acid (Sigma-Aldrich Chemie 
GmbH, Munich, Germany)] for 5 min to reversibly stain protein bands and therefore confirm 
correct protein transfer. After destaining of proteins by washing with dH2O, the membrane 
was blocked in 4% non-fat milk powder (AppliChem, Darmstadt, Germany) in PBS for 1 hour 
at RT followed by incubation with the appropriate primary antibody diluted in 1% milk in 
PBST-0.05% overnight at 4°C. Specific dilutions of primary antibodies are listed in Table 2.1. 
The membrane was then washed three times in PBST for 10 min at RT followed by 
incubation with the appropriate HRP conjugated secondary antibody 1:2000 in PBST for 
1 hour at RT. After three washing steps in PBST for 20 min each, proteins were detected by 
enhanced chemiluminesence using Pierce™ ECL Western Blotting Substrate (Thermo Fisher 
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Scientific, Waltham, MA, USA) or Amersham™ ECL Prime Western Blotting Detection 
Reagent (GE Healthcare Life Sciences, Little Chalfont, United Kingdom) when higher 
sensitivity was needed. The emitted light signal was subsequently visualized on CL-XPosure™ 
X-ray films (Thermo Fisher Scientific, Waltham, MA, USA). 
 
2.2.6.3. Electrochemiluminescence (ECL) assay for α-Synuclein quantification 
α-Synuclein was quantified in total CSF and plasma and in exosomes derived from both fluids 
by using an electrochemiluminescence assay according to Kruse et al. (2012). The technology 
of this assay is based on a sandwich enzyme-linked immunosorbent assay (ELISA) technique 
with high sensitivity due to the ECL based detection system.  
96-well standard plates (Meso Scale Discovery™, Gaithersburg, MD, USA) were coated with 
30 µl capture antibody MJF-1 clone 12.1 (kindly provided by Dr. Liyu Wu; Epitomics, 
Burlingame, USA) at 3 µg/ml in PBS and incubated overnight at 4°C. Plates were then washed 
three times with 150 µl PBST followed by blocking with 150 µl 1% bovine serum albumin 
(BSA) in PBST (BSA; SeraCare Life Sciences, Milford, MA, USA) for 1 hour at RT with shaking 
at 300 rounds per minute (rpm). After three times washing, 25 µl of recombinant 
α-Synuclein standards (kindly provided by Dr. Omar El-Agnaf, Hamad Bin Khalifa University, 
Doha, Qatar) and samples were applied to the wells in duplicates and incubated for 1 hour at 
RT and under shaking at 700 rpm. More specific, total CSF and plasma samples were diluted 
1:8 and a 1:4 serial dilution of recombinant α-Synuclein starting at 25 ng/ml was prepared in 
1% BSA. Purified exosome samples were applied without further dilution. Plates were 
washed again three times and Sulfo-TAG-labelled anti-α-Synuclein clone 42 (BD Biosciences, 
Le Pont de Claix, France) was applied at 1 µg/ml for 1 hour at RT and shaking at 700 rpm. 
After three times washing 150 µl of 2x Read Buffer T (Meso Scale Discovery™) was added to 
each well and plates were measured at 620 nm in a Sector Imager 6000 (Meso Scale 
Discovery™). Data analysis was performed with the MSD Discovery Workbench 3.0 Data 
Analysis Toolbox (Meso Scale Discovery™). 
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2.2.6.4. Quantification of CSF Tau levels 
The concentration of total CSF Tau protein was determined by using the commercial 
available INNOTEST® hTAU Ag sandwich ELISA kit (Innogenetics N.V., Ghent, Belgium). The 
assay was performed according to the manufacturer`s instructions. 
 
2.2.6.5. Gaussia luciferase protein-fragment complementation assay 
The fusion constructs α-Synuclein-hGLuc1 (S1) and α-Synuclein-hGLuc2 (S2) were 
transfected into H4 cells followed by treatment with CSF derived exosomes as described in 
section 2.2.5.2. After 12 h of transfection, cells were washed once with PBS and fresh serum- 
and phenol red free medium was added. Luciferase activity resulting from protein 
complementation was measured in live cells in an automated plate reader at 480 nm 
immediately after adding 20 µM of the cell permeable substrate Coelenterazine (PJK GmbH, 
Kleinblittersdorf, Germany) to each well. Luminescence signals were integrated for 
2 seconds. The protein-fragment complementation assay (including cell transfection and 
treatment with exosomes) was performed by Prof. Dr. Karin Danzer`s research group 
(Department of Neurology, Ulm University). 
 
2.2.7. Data and statistical analysis 
Data and statistical analyses were performed with MS Office Excel 2010 software (Microsoft, 
Redmond, WA, USA), GraphPad Prism® 6 software (GraphPad Software Inc., San Diego, CA, 
USA) and SPSS Statistics 17.0 software (IBM Corporation, Armonk, NY, USA). For normally 
distributed data sets the Student`s t test or one-way ANOVA followed by Games-Howell post 
hoc test (for data resulting from unequal sample size and variance) were performed. The 
nonparametric Mann-Whitney U-test was used when normal distribution was not given. 
P values less than 0.05 were regarded as significantly different. Results were shown as the 
mean and the standard error of the mean (SEM) and were illustrated with MS Office Excel 
and GraphPad Prism®. Correlation analysis was performed by using Pearson`s correlation 
and Receiver Operating Characteristics (ROC) curves were used to evaluate the diagnostic 
performance of exosomal α-Synuclein as a diagnostic marker. Data were analyzed blinded to 
the diagnosis. 
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2.2.8. RNA extraction from exosomes 
Total RNA was extracted from purified CSF exosomes or primary neuronal culture exosomes 
under RNAse-free conditions using TRI Reagent® (Sigma-Aldrich Chemie GmbH, Munich, 
Germany). Exosome pellets (dissolved in 200 µl TRI Reagent®, see section 2.2.3.1 and 
2.2.5.3) were filled up to 1 ml with TRI Reagent® followed by the addition of 3 µl Glycogen 
[25 µg/ml in diethylpyrocarbonate (DEPC) treated water]. The mixture was incubated for 
5 min at RT. 200 µl of Chloroform was then added, samples were mixed by vigorous shaking 
and incubated for 5 min at RT. For phase separation, samples were centrifuged for 15 min at 
12,000 x g and 4°C. The RNA containing aqueous upper phase was carefully transferred into 
a fresh tube followed by precipitation with 500 µl Isopropanol overnight at −20°C. The 
following steps were all carried out at 4°C. After centrifugation for 30 min at 12,000 x g, the 
supernatant was carefully discarded and the pellet was washed two times in 750 µl 75% 
Ethanol. The RNA pellet was air-dried until it was invisible and dissolved in 10 µl RNAse-free 
water. 
Exosomal RNA yield was measured by NanoDrop 2000 spectrophotometer (Thermo 
Scientific, Waltham, MA, USA) and RNA quality was analyzed with an Agilent 2100 
Bioanalyzer by using RNA 6000 Pico Chips on the appropriate total Eukaryotic pico 6000 RNA 
assay (all from Agilent Technologies, Santa Clara, CA, USA) in accordance to the 
manufacturer`s instructions. RNA samples were then stored at −80°C until sequencing. 
 
2.2.9. Next Generation Sequencing (NGS) of small ncRNAs 
NGS sequencing of small ncRNAs was carried out using a HighSeq™ 2000 system (Illumina, 
San Diego, USA). Small RNA libraries were prepared from total RNA extracted from CSF or 
primary cortical/hippocampal neuronal exosomes using the TruSeq Small RNA Library Kit 
according to the provided protocols from Illumina. Since exosomes contain relatively low 
amounts of RNA and the starting volume of CSF was 500 µl, a minimum of 0.5 ng of total 
RNA was used as starting material. 
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2.2.9.1. Bioinformatics and statistical analysis 
Raw data obtained from NGS sequencing and the generation of small ncRNA reads were 
performed by the group of Dr. Stefan Bonn, German Center for Neurodegenerative Diseases, 
Göttingen, Germany. In short, quality assessment of RNA libraries and detection of small 
ncRNAs was performed using Oasis web platform (Capece et al., 2015) and comprised 
lengths filtering (15 – 32 nucleotides) of reads followed by their mapping to the reference 
genome. 
All statistical and functional analyses, including feature selection via the application of 
machine learning approaches and statistical methods and further development and 
application of an algorithm that can differentiate AD patients from controls, were performed 
by Gaurav Jain under supervision of Prof. Dr. André Fischer, German Center for 




3. Results| 37 
 
3. Results 
3.1. Characterization of exosomal α-Synuclein in CSF and plasma 
from patients with Parkinson`s disease and dementia with Lewy 
bodies 
We analyzed CSF and plasma exosomal α-Synuclein as a potential biomarker in different 
diseases with and without α-Synuclein related neurodegeneration. The characterization of 
CSF and plasma exosomal α-Synuclein from patients with PD, DLB, PSP as an example of a 
non-α-Synuclein related neurodegenerative disease with Parkinson syndrome and 
neurological, non-neurodegenerative controls included the quantification of exosome 
numbers and exosomal α-Synuclein protein concentrations as well as determination of the 
potential of CSF exosomes to induce the aggregation of soluble α-Synuclein in a reporter cell 
assay. 
Most of the results from section 3.1 have been published in: 
 
Induction of α-Synuclein aggregate formation by CSF exosomes from patients 
with Parkinson`s disease and dementia with Lewy bodies  
Anne Stuendl, Marcel Kunadt, Niels Kruse, Claudia Bartels, Wiebke Moebius, Karin M. 
Danzer, Brit Mollenhauer and Anja Schneider 
Brain: a journal of neurology (2016) 139, 481-494.  
 
3.1.1. Purification of exosomes from cerebrospinal fluid 
Exosomes were purified from CSF by serial centrifugation rounds including a final UC step at 
100,000 x g as described previously (Kunadt et al., 2015). The 100,000 x g pellet and total 
CSF were analyzed for exosome numbers and α-Synuclein concentrations (Figure 3.1A). 
Analysis of the UC pellet by electron microscopy revealed vesicles of 40 to 120 nm diameter 
and the typical cup shaped morphology of exosomes (Figure 3.1B). Next, purified CSF 
exosome and total CSF fractions were tested by WB analysis for the presence of the 
exosomal marker protein Flotillin-2 which was detectable in the exosome fraction but absent 
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in total CSF (Figure 3.1C, left panel). In contrast, the heavy and light chains of IgG were 
detected in total CSF but not in the exosome fraction (Figure 3.1C, middle panel) indicating 
that the UC pellet was not contaminated by protein complexes. To further verify the purity 
of the isolated exosomes and to rule out microsomal contaminations, exosomes and total 
CSF as well as a N2a cell lysate were immunostained against the endoplasmatic reticulum 




Figure 3.1: Purification and characterization of exosomes from CSF. (A) Exosomes were purified from 500 µl 
CSF by serial centrifugation rounds with a final ultracentrifugation step at 100,000 x g. Exosome numbers and 
α-Synuclein concentrations were quantified in total CSF and exosome fractions by NTA and ECL assay. (B) The 
exosome pellet derived from 4 ml CSF was subjected to electron microscopy and individual exosomes showed 
the typical cup shaped morphology. Scale bar = 100 nm. (C) Western Blot analysis of exosomes derived from 
2.5 ml CSF and the corresponding total CSF fraction. The exosome pellet was resuspended in 20 µl 5x protein 
sample buffer and total CSF was diluted 1:5 in sample buffer. 20 µl of the exosome preparation and 20 µl of 
total CSF were immunostained against the exosomal marker protein Flotillin-2 (left panel) and with a secondary 
antibody against human IgG as a negative control (middle panel). 20 µl of the exosome pellet, total CSF and 
N2a cell lysate were probed with an antibody against the edoplasmatic reticulum protein Calnexin to exclude 
microsomal contaminations in the exosome fraction (right panel). 
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3.1.2. Quantification of CSF exosomes and exosomal α-Synuclein concentrations 
To quantitatively analyse exosome numbers and their size in total CSF as well as in CSF 
exosome preparations, we used nanoparticle tracking analysis. Exosomes were purified from 
500 µl CSF, dissolved in PBS and measured in triplicates. Figure 3.2A shows a representative 
graph of total CSF (red line) and the corresponding exosome preparation (blue line). Vesicle 
size in total CSF ranged from zero to 550 nm with several peak fractions. In contrast, the 
purified exosome sample predominantely contained vesicles in the size range of exosomes 




Figure 3.2: Quantitative analysis of CSF exosomes. (A) Size distribution profile showing vesicle numbers of a 
CSF exosome preparation from 500 µl CSF and the corresponding total CSF measured by NTA (total CSF: red 
line; exosome pellet: blue line; peak at 102 nm). The values were adjusted for the particular dilution factors 
and calculated to represent the absolute vesicle numbers in 1 ml CSF and in exosomes derived from the same 
CSF volume. (B) α-Synuclein levels in total CSF and CSF exosomes were quantified by using a highly sensitive 
ECL assay. A resulting plot of α-Synuclein standards (blue circles, standard curve = blue line) and CSF exosome 
samples (red diamonds) is shown and reveals that α-Synuclein levels in exosome samples are found in the 
linear detection range of the assay. (C) The coefficient of variance was calculated for the number of exosomes, 
α-Synuclein levels and the ratio of exosomal α-Synuclein protein levels to the number of exosomes in both, the 
exosome preparation and in total CSF. Therefore, CSF replicate samples of n = 3 and n = 4 from two different 
patients were analyzed. Values are given as mean ± SEM. 
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In order to use CSF exosomes as a potential biomarker in synucleinopathies, the necessary 
CSF volume should not exceed a maximum of 500 to 1000 µl and should allow for automated 
and quantitative analysis. To this end, we used an optimized ELISA, based on an ECL 
platform, that allows α-Synuclein quantification with high sensitivity and in a large dynamic 
range (Kruse et al., 2012). The ECL assay has an average lower detection limit of 5 pg/ml and, 
as shown in Figure 3.2B, all measured α-Synuclein levels in exosome preparations derived 
from 500 µl CSF (red dots) were found in the detection range of the assay. To verify the 
reproducibility of the NTA and ECL quantification methods, exosomes were purified from 
three or four aliquots of the same CSF sample (two different CSF samples in total) and 
quantified for exosome numbers and α-Synuclein levels. Measurements were also 
performed for the corresponding total CSF. The coefficient of variance (CV) was below 10% 
for the number of exosomes (9.4%) and α-Synuclein levels (8.2%) in total CSF whereas CV 
values for the same measurements in the exosome fraction were 22.3% for the number of 
exosomes as well as for α-Synuclein levels (Figure 3.2C). Further, CV calculations for the ratio 
of exosomal α-synuclein levels to the number of exosomes revealed values of 9.9% in the 
exosome preparation and 8.2% in the total CSF fraction. These values indicate that the 
exosome preparation is suitable for quantitative analysis in patient samples. 
 
 
3.1.3. Quantification of CSF exosomal α-Synuclein in early stage PD patients 
First, we analyzed exosomal α-Synuclein protein levels from CSF samples obtained from drug 
naïve patients with early stage PD and healthy controls. 76 patients diagnosed with PD and 
58 age- and gender-matched healthy controls were obtained from the longitudinal DeNoPa 
cohort (Mollenhauer et al., 2013a) (see section 2.2.2.2 for detailed description of the cohort 
and Table 6.1 for demographic information of the analyzed CSF samples). Exosomes were 
purified from 500 µl CSF followed by the quantification of α-Synuclein protein levels in total 
CSF (Figure 3.3A) and in the exosome fraction (Figure 3.3B). All values were normalized to 
1 ml CSF starting volume. α-Synuclein levels in total CSF were significantly lower in PD 
patients compared to the healthy control group (PD mean α-Synuclein = 647.88 pg/ml, 
SEM = 26.95 pg/ml, n = 76; healthy controls mean α-Synuclein = 774.64 pg/ml, 
SEM = 36.13 pg/ml, n = 58; * p < 0.05, Student`s two-sided t-test; Figure 3.3A).  
3. Results| 41 
 
This observation is consistent to the findings previously described in Mollenhauer et al. 
(2013b). In addition, we observed a significant lower amount of absolute α-Synuclein in CSF 
exosomes derived from PD patients compared to healthy controls (Figure 3.3B; PD 
mean = 13.04 pg α-Synuclein in exosomes derived from 1 ml CSF, SEM = 0.61 pg, n = 76; 
healthy controls mean  = 16.01 pg α-Synuclein derived from 1 ml CSF, SEM = 0.98 pg, n = 58; 
* p < 0.05, Student`s two-sided t-test). Furthermore, we calculated the ratio of α-Synuclein 
in exosomes to total α-Synuclein in the CSF starting volume (Figure 3.3C). Here, we observed 
that only a small portion (2.17%) of total CSF α-Synuclein is localized in exosomes with no 
significant difference between PD patients and the healthy control group (PD mean = 2.17%, 




Figure 3.3: Quantification of exosomal α-Synuclein in CSF from patients with PD and healthy controls from 
the DeNoPa cohort. (A) α-Synuclein concentrations in total CSF from PD patients (red bar) are lower as 
α-Synuclein levels in healthy control patients (grey bar), n = 76 PD patients, n = 58 healthy control patients, 
* p < 0.05, two-sided t-test. (B) α-Synuclein protein levels were quantified in CSF exosome preparations from 
PD patients (red bar) and healthy control patients (grey bar). Exosomes were purified from 500 µl CSF and 
protein levels were normalized to 1 ml. N = 76 PD patients, n = 58 healthy control patients, * p < 0.05, two-
sided t-test. (C) The ratio of exosomal α-Synuclein to α-Synuclein present in total CSF was calculated in PD 
patient samples (red bar) and healthy control samples (grey bar) and is shown in %. No significant difference is 
detected. Exosomes were prepared from 500 µl CSF and α-Synuclein values were normalized to 1 ml for both, 
exosomes and total CSF. N = 76 PD patients, n = 58 healthy control patients, n.s. = not significant, two-sided 
t-test. All values are given as mean ± SEM.  
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3.1.4. Characterization of CSF exosomal α-Synuclein in PD, DLB, and 
non-α-Synuclein related disease controls 
We next studied CSF exosomal α-Synuclein in more progressed PD stages. We obtained CSF 
samples from 37 patients diagnosed with PD according to UK Brain Bank criteria from the 
Kassel cohort. Selected subjects showed different grades of motor symptoms as assessed by 
Hoehn and Yahr staging (mean H&Y stage = 3.9, SEM = 0.20). These samples were further 
complemented with 35 patients suffering from DLB as a second α-Synuclein related disease 
with Parkinson syndrome and two different control groups. The first control group contained 
15 patients with polyneuropathy (PNP) who presented with gait disturbances but, after 
thorough clinical assessment, were diagnosed with PNP and no Parkinson syndrome. The 
second control group consisted of 25 patients with progressive supranuclear palsy (PSP). 
These patients show a characteristic Parkinson syndrome caused by Tau pathology. All 
samples were randomly selected from the Kassel cohort (Mollenhauer et al., 2011). In 
addition, 3 DLB CSF samples were provided from the Göttingen cohort to increase sample 
size numbers. Demographic information of the selected samples is given in Table 6.2).  
 
3.1.4.1. Comparison of CSF exosomal α-Synuclein levels in PD, DLB, PNP and PSP 
When analyzing the absolute levels of α-Synuclein in exosome preparations derived from the 
same CSF volume after normalization to 1 ml, we did not observe significant differences 
between the PD, PNP and PSP groups (Figure 3.4A; PD mean = 17.20 pg α-Synuclein in 
exosomes derived from 1 ml CSF, SEM = 1.50 pg, n = 36; PNP mean = 17.20 pg in exosomes 
derived from 1 ml CSF, SEM = 2.97 pg, n = 15; PSP mean = 20.60 pg α-Synuclein in exosomes 
derived from 1 ml CSF, SEM = 4.56 pg, n = 25, one-way ANOVA p = 0.000691, Games-Howell 
post hoc test revealed no significant differences). Interestingly, this is in contrast to our 
findings from the DeNoPa cohort, where exosomal α-Synuclein levels were slightly lower in 
PD samples (see 3.1.3 and Figure 3.3B). We also measured total α-Synuclein amounts in 
exosome fractions from 35 DLB patients. Here, significant lower α-Synuclein levels were 
found compared to all other patient groups as depicted in Figure 3.4A (DLB mean = 7.92 pg 
α-Synuclein in exosomes derived from 1 ml CSF, SEM = 0.78 pg, one-way ANOVA 
p = 0.000691 followed by Games-Howell post hoc test, (*) p = 0.05, * p < 0.05, 
*** p < 0.0005). Additionally, α-Synuclein levels were determined in total CSF fractions of 
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the four different patients groups. As shown in Figure 3.4B, α-Synuclein was found to be 
significantly less abundant in DLB CSF than in total CSF of PD patients (DLB 
mean = 380.61 pg/ml, SEM = 27.55 pg/ml; PD mean = 602.42 pg/ml, SEM = 59.79 pg/ml; PNP 
mean = 615.86 pg/ml, SEM = 122.47 pg/ml; PSP mean = 467.65 pg/ml, SEM = 78.74 pg/ml, 
one-way ANOVA, p = 0.0202, followed by Games-Howell post hoc test, * p = 0.05). As 
already observed with α-Synuclein levels in exosomes (Figure 3.4A), total α-Synuclein levels 
in PD CSF did not differ significantly from those in CSF from control patients (PNP and PSP, 
Figure 3.4B). Again, this finding is in contrast to the small reduction of α-Synuclein protein 
level in total CSF from early-stage PD patients of the DeNoPa cohort (Figure 3.3A).  
 
 
Figure 3.4: α-Synuclein levels in CSF exosomes and total CSF from patients with PD, DLB and non-
α-Synuclein related disease controls in the Kassel cohort. (A) α-Synuclein protein levels were determined in 
exosomes prepared from 500 µl CSF from patients with DLB (green bar), PD (red bar), PNP (dark blue bar) and 
PSP (light blue bar). Protein values were then normalized to 1 ml, n = 35 DLB patients, n = 36 PD patients, 
n = 15 PNP patients and n = 25 PSP patients. DLB exosomes exhibit lower α-Synuclein levels compared to all 
other patients groups. One-way ANOVA indicated significant differences (p = 0.000691) and Games-Howell post 
hoc test was applied, (*) p = 0.05, * p < 0.05, *** p < 0.0005. (B) Quantification of α-Synuclein concentrations in 
total CSF from patients with DLB (green bar, n = 32), PD (red bar, n = 32), PNP (dark blue bar, n = 15) and PSP 
(light blue bar, n = 25). α-Synuclein is less abundant in DLB CSF compared to PD CSF, one-way ANOVA 
(p = 0.0202), Games-Howell post hoc test, * p = 0.05. All values are shown as mean ± SEM. 
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3.1.4.2. CSF exosomal α-Synuclein correlates with cognitive impairment in DLB 
patients 
Next, we plotted CSF exosomal α-Synuclein levels against the Mini-mental State Examination 
(MMSE) scores. The MMSE is a screening test for dementia which covers different cognitive 
domains such as orientation, language, memory and visuoconstruction (Folstein et al., 1975) 
(see also Table 3.1.). A MMSE score between 0 – 10 indicates severe dementia, 11 – 20 
moderate dementia and above 20 mild dementia. Test scores between 27 – 30 can be 
observed in non-demented individuals. 
 
Table 3.1: Mini-mental State Examination after Folstein et al. (1975). 
Maximum Score  
  Orientation 
5 (    ) What is the (year) (season) (date) (day) (month)? 
5 (    ) Where are we (state) (country) (town) (hospital) (floor)? 
   
  Registration 
3 (    ) name 3 objects: 1 second to say each. Then ask the patient all 3 after you 
  have said them. Give 1 point for each correct answer. 
  Then repeat them until he/she learns all 3. Count trials and record. 
  Trials  
   
  Attention and Calculation 
5 (    ) Serial 7`s. 1 point for each correct answer. Stop after 5 answers. 
  Alternatively spell “world” backward. 
   
  Recall 
3 (    ) Ask for the 3 objects repeated above. Give 1 point for each correct answer. 
   
  Language 
2 (    ) Name a pencil and watch. 
1 (    ) Repeat the following “No ifs, ands, or buts” 
3 (    ) Follow a 3-stage command: 
  “Take a paper in your hand, fold it half, and put it on the floor” 
1 (    ) Read and obey the following: CLOSE YOUR EYES 
1 (    ) Write a sentence. 
1 (    ) Copy the design 
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We found an inverse correlation of exosomal α-Synuclein levels and MMSE scores in 32 DLB 
patients (for 3 DLB subjects no MMSE data were available) indicating that higher α-Synuclein 
protein levels in exosomes are associated with lower MMSE scores and therefore with 
impaired cognitive function (Figure 3.5A, Pearson`s correlation coefficient r = −0.382, 
p = 0.028, two-tailed probability, n = 32). We next tested for a correlation of CSF exosomal 
α-Synuclein with CSF Tau levels, as CSF Tau is a general marker of neurodegeneration, 
presumably caused by an increased release of Tau from disintegrating neurons. We 
observed a strong positive correlation for the 17 DLB patients for whom both values were 
available (Figure 3.5B, Pearson`s correlation coefficient r = 0.751, p = 0.0005, two-tailed 
probability). These data demonstrate that higher α-Synuclein protein levels in CSF exosomes 
are associated with increased CSF Tau levels.  
 
 
Figure 3.5: Exosomal α-Synuclein correlates with cognitive impairment and neurodegeneration in DLB 
patients. (A) Correlation of α-Synuclein levels in CSF exosomes with impaired cognitive function in DLB 
patients. Cognitive function was measured by Mini-Mental State Examination (MMSE) test with low scores 
indicating decreased cognitive function. N = 32, Pearson`s correlation was applied for statistical analysis, 
coefficient r = −0.382, p = 0.028, two-tailed probability. (B) α-Synuclein levels in CSF exosomes correlate with 
the increase of Tau protein levels in total CSF from DLB patients indicating progressive neurodegeneration. 
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3.1.4.3. CSF exosomal α-Synuclein does not correlate with severity of motor symptoms 
in PD patients 
To examine whether CSF exosomal α-Synuclein levels correlate with disease progression in 
PD, we plotted exosomal α-Synuclein values of 36 PD patients against their individual H&Y 
stage score. The H&Y score distinguishes the severity of motor symptoms on a scale from 
one to five, with higher scores reflecting more severe deficits (Hoehn and Yahr, 1967) (see 
also Table 3.2). As shown in Figure 3.6, no correlation was observed between exosomal 
α-Synuclein levels and motor deficits in PD patients (Pearsons`s correlation coefficient 
r = −0.011, p = 0.950, two-tailed probability, n = 36). 
Table 3.2: Hoen and Yahr scale 
Stage H&Y Scale 
1 Only unilateral involvement, usually with minimal or no functional disability 
2 Bilateral or midline involvement without impairment of balance 
3 Bilateral disease: mild to moderate disability with impaired postural reflexes; 
physically indpendent 
4 Severly disabling disease, still able to walk or stand unassisted 
5 Confinement to bed or wheelchair unless aided 
 
 
Figure 3.6: Exosomal α-Synuclein does not correlate with the severity of motor symptoms in PD patients. 
Correlation analysis of CSF exosomal α-Synuclein levels with motor symptoms in PD patients. Motor symptoms 
were classified by Hoen and Yahr staging (H&Y) with higher numbers indicating decreased motor performance. 
N = 36, Pearson`s correlation coefficient r = −0.011, p = 0.950, two-tailed probability. 
  
3. Results| 47 
 
3.1.4.4. CSF exosome numbers differ between the different diagnostic groups 
We next measured exosome numbers normalized to the number of exosomes in 1 ml CSF in 
the different diagnostic groups. Figure 3.7 illustrates that the PD group revealed the highest 
number of exosomes among all groups with almost four-fold higher values as compared to 
the DLB group, which in turn exhibited the lowest number of exosomes (PD 
mean = 3.69 × 109 exosomes/ml CSF, SEM = 1.83 × 108 exosomes/ml CSF, n = 37; DLB 
mean = 1.08 × 109 exosomes/ml CSF, SEM = 1.83 × 108 exosomes/ml CSF, n = 30; one-way 
ANOVA p < 0.0001 followed by Games-Howell post hoc test, *** p < 0.0005). The number of 
exosomes was also two-fold higher in PD CSF as compared to the PNP and PSP control 
groups (PNP mean = 2.03 × 109 exosomes/ml CSF, SEM = 4.09 × 108 exosomes/ml CSF, 
n = 15; PSP mean = 1.39 × 109 exosomes/ml CSF, SEM = 5.23 × 108 exosomes/ml, n = 24; 
Games-Howell post hoc test, * p < 0.05). Between the PNP and PSP control groups, no 
significant differences were observed.  
 
 
Figure 3.7: Characterization of CSF exosome numbers from DLB, PD, PNP and PSP patient groups. (A) 
Numbers of exosomes were determined by NTA followed by normalization to exosome numbers in 1 ml CSF. 
Exosome numbers differ highly between the groups; DLB (green bar, n = 30), PD (red bar, n = 37), PNP (dark 
blue bar, n = 15) and PSP (light blue bar, n = 24). For statistical analysis one-way ANOVA was applied 
(p < 0.0001) followed by Games-Howell post hoc test, * p < 0.05, *** p < 0.0005. (B) Ratio of exosomal 
α-Synuclein (CSF exosomal α-Synuclein levels are shown in Figure 3.4) to the number of exosomes in 1 ml CSF 
from patients with DLB (green bar, n = 28), PD (red bar, n = 35), PNP (dark blue bar, n = 15) and PSP (light blue 
bar, n = 24). One-way ANOVA revealed statistical significance (p = 0.000377) and Games-Howell post hoc test 
was applied, * p < 0.05. Values are given as mean ± SEM. 
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Furthermore, the ratio of exosomal α-Synuclein to the number of exosomes present in 1 ml 
starting volume of CSF was calculated for DLB, PD, PNP and PSP groups (Figure 3.7B). Here, 
we found a two- to three-fold lower ratio in PD CSF compared to the other groups, indicating 
that PD patients contain less α-Synuclein protein per exosomal particle than patients of all 
other groups (PD mean = 6.74 × 10−9 pg α-Synuclein/number of exosomes, 
SEM = 1.04 × 10−9  pg α-Synuclein/number of exosomes, n = 35; DLB mean = 1.50 × 10−8 pg 
α-Synuclein/number of exosomes, SEM = 3.37 × 10−9 pg α-Synuclein/number of exosomes, 
n = 28; PNP mean = 2.63 × 10−8 pg α-Synuclein/number of exosomes, SEM = 1.03 × 10−8 pg 
α-Synuclein/number of exosomes, n = 15; PNP mean = 4.99 × 10−8 pg α-Synuclein/number of 
exosomes, SEM = 1.27 × 10−8 pg α-Synuclein/number of exosomes, n = 24; one-way ANOVA 
revealed significant differences, p = 0.000377, Games-Howell post hoc test, * p < 0.05). We 
did not find significant differences between the PNP and PSP groups. 
 
 
3.1.5. Diagnostic performance of CSF exosomal α-Synuclein as a potential 
biomarker in α-Synuclein related disorders 
We next evaluated the diagnostic performance of CSF exosomal α-Synuclein and the ratio of 
exosomal α-Synuclein to the number of CSF exosomes as potential biomarkers in a 
preliminary trial (Figure 3.8). ROC curve analysis of exosomal α-Synuclein to distinguish DLB 
from PD revealed a sensitivity and specificity of 85.7% and 80.6% with a positive predicitive 
value of 81.1% and a negative predictive value of 85.3% (Table 3.3). ROC curve analysis of 
exosomal α-Synuclein to discriminate between DLB and PNP exhibited values of 85.7% for 
the sensitivity and 66.7% for specificity and positive and negative prediction were 83.3% and 
64.3%, respectively (Table 3.3). The sensitivity and specificity for the distinction of DLB from 
PSP samples were 71.4% and 92.0% with positive and negative predictive values of 92.9% 
and 71.8% (Table 3.3). Calculated AUC values, indicating the overall quality of the test to 
distinguish between two diagnostic groups, were between 0.804 and 0.883 for exosomal 
α-Synuclein (Figure 3.8A,C,D).  
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Figure 3.8: Diagnostic performance of CSF exosomal α-Synuclein and the ratio of CSF exosomal α-Synuclein 
to the number of exosomes. Receiver operating characteristics (ROC) curve analysis was performed to examine 
the diagnostic value of CSF exosomal α-Synuclein levels as well as of the ratio exosomal α-Synuclein to the 
number of exosomes. (A) ROC curve of exosomal α-Synuclein in CSF to distinguish DLB from PD, area under the 
curve (AUC) = 0.883, p < 0.001. (B) ROC curve of the ratio exosmal α-Synuclein to the number of exosomes to 
discriminate between DLB and PD, AUC = 0.665, p = 0.025. (C) ROC curve of α-Synuclein levels in exosomes to 
distinguish DLB from PNP, AUC = 0.804, p = 0.001 and (D) to distinguish DLB from PSP, AUC = 0.864, p < 0.001. 
(E) ROC curve of the ratio of exosomal α-Synuclein to the number of exosomes to discriminate between PD and 
PNP, AUC = 0.741, p = 0.007 and (F) to discriminate between PD and PSP, AUC = 0.906, p < 0.001. Values for 
sensitivity, specificity and prediction are listed in Table 3.3 and Table 3.4. 
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In addition, we performed ROC curve analysis of the ratio of exosomal α-Synuclein to the 
number of exsomes in CSF and we observed a sensitivity of 74.3% and a specificity of 60.7% 
for the discrimination of PD patients from DLB patients (Table 3.4). The sensitivity was high 
(94.3%) to distinguish PD from PNP, whereas the specifity was only 46.7% (Table 3.4). We 
also detected high values for the sensitivity (94.3%) and moderately high levels of specificity 
(79.2%) to differentiate between PD and PSP (Table 3.4). The positive and negative 
predictive values for this marker were between 68.4% and 82.1% for positive prediction and 
between 64.0% and 90.4% for negative prediction. Calculation of AUC values showed values 
between 0.665 for the discrimination of PD and DLB (Figure 3.8B), 0.741 for the 
discrimination of PS and PNP (Figure 3.8E) and 0.906 to distinguish PD from PSP (Figure 
3.8F).  
Table 3.3: Exosomal α-Synuclein [pg] in 1 ml CSF 















0.883 < 0.001 11.34 85.7 80.6 81.1 85.3 
DLB versus 
PNP 
0.804 = 0.001 11.46 85.7 66.7 83.3 64.3 
DLB versus 
PSP 
0.864 < 0.001 9.23 71.4 92.0 92.9 71.8 
 
Table 3.4: Exosomal α-Synuclein [pg]/number of exosomes, 1 ml CSF 
 AUC P-value Cut-off Value 














0.665 0.025 0.75 74.3 60.7 68.4 64.0 
PD versus 
PNP 
0.741 0.007 1.30 94.3 46.7 80.5 77.8 
PD versus 
PSP 
0.906 < 0.001 1.27 94.3 79.2 82.1 90.4 
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3.1.6. CSF exosomes from PD and DLB patients induce the aggregation of 
α-Synuclein in vitro 
We hypothesized that exosomes might contribute to the spreading of pathological 
α-Synuclein species by the transfer of aggregated α-Synuclein to healthy neurons. Here, they 
could act as a seed to induce the aggregation of soluble α-Synuclein. To study the potential 
of CSF exosomes to induce α-Synuclein aggregation we incubated CSF derived exosomes 
from patients with PD, DLB and neurological controls with a reporter cell line to detect 
α-Synuclein aggregation. In this Gaussia luciferase protein-fragment complementation assay 
split luciferase fragments [either N-terminal (S1) or C-terminal (S2) fragment], that are not 
active in their state, are fused to the C-terminus of α-Synuclein and were transiently 
expressed in H4 cells (Figure 3.9A). Physical interaction of the α-Synuclein molecules results 
in active luciferase due to the close proximity and complementation of the split fragments 
which can be measured as a luminescence signal in the presence of a luciferase substrate. 
The protein-fragment complementation assay was kindly performed by Prof. Dr. Karin 
Danzer`s research group (Department of Neurology, Ulm University). 
To study the effect and seeding potential of CSF derived exosomes on the induction of 
aggregation of soluble α-Synuclein in cells, exosomes were purified from the same volume of 
CSF from patients with DLB, PD and neurological controls. All CSF specimens were randomly 
selected from the Kassel cohort and the control patient group consisted of 6 PNP patients, 
1 patient with normal pressure hydrocephalus and 1 patient suffering from corticobasal 
degeneration. Previously transfected cells were then treated with purified CSF exosomes 
and the seeding capacity of exosomes was quantified. Quantification of α-Synuclein 
interaction was calculated as fold luminescence increase of the luminescence signal 
measured in α-Synuclein transfected and CSF exosome treated cells compared to mock 
treated control cells. Control cells were incubated with CSF exosomes but were not 
transfected with the two α-Synuclein constructs, only transfection reagent was added. To 
rule out unspecific interaction of both luciferase fragments, a series of control experiments 
was performed previously by Danzer et al. (2011). Here, no luciferase activity changes were 
reported for the co-transfection of α-Synuclein S1 with Aβ fused to the C-terminal luciferase 
fragment nor for the combination of α-Synuclein S2 with Aβ fused to the N-terminal 
fragment of luciferase. 
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As shown in Figure 3.9B, we observed an approximately two-fold increase of the 
luminescence signal in H4 cells treated with PD derived exosomes compared to cells treated 
with DLB and neurological control exosomes (DLB mean = 6.40 fold increase, SEM = 0.77 fold 
increase, n = 9; PD mean = 15.79 fold increase, SEM = 1.73 fold increase, n = 10 and 
neurological control mean = 8.79 fold increase, SEM = 1.58 fold increase, n = 7, one-way 
ANOVA, p = 0.000513, followed by Student`s two-sided t-test, * < 0.05). Thus, PD derived 
CSF exosomes exhibit a higher capacity to induce the aggregation of soluble α-Synuclein in 
cells. 
As reported in sections 3.1.4.1 and 3.1.4.4, α-Synuclein levels and the number of exosomes 
are significantly decreased in CSF derived from DLB patients compared to PD and 
neurological controls. We therefore calculated the potential of CSF exosomes to induce 
aggregation of soluble α-Synuclein after normalizing for exosomal α-Synuclein content in 
each sample (Figure 3.9C). To this end, we calculated the ratio of fold luminescence increase 
to exosomal α-Synuclein content of each sample. Interestingly, after normalizing for 
exosomal α-Synuclein content, both, PD and DLB exosomes had a stronger aggregate 
inducing effect on α-Synuclein compared to neurological controls [DLB mean = 2.43 fold 
luminescence increase/pg exosomal α-Synuclein, SEM = 1.05 fold luminescence increase/pg 
exosomal α-Synuclein, n = 8; PD mean = 2.87 fold luminescence increase/pg exosomal 
α-Synuclein, SEM = 0.95 fold luminescence increase/pg exosomal α-Synuclein, n = 9; 
neurological control mean = 1.50 fold luminescence increase/pg exosomal α-Synuclein, 
n = 6; one-way ANOVA revealed significant difference, p = 0.00698, (*) p < 0.10 indicates 
strong statistical tendency due to the small sample size, * p < 0.05, Mann-Whitney U-test].  
As shown in (Figure 3.9D), a strong correlation between exosomal α-Synuclein content and 
the potential to induce α-Synuclein aggregation was observed for exosomes from DLB (green 
diamonds, n = 8) and PD patients (red rectangles, n = 9) but not for exosomes from the 
control group (blue triangles, n = 6; Pearson`s correlation coefficient for DLB and PD: 
r = 0.85, p = 1.6 × 10-5, n = 17; control group: r = −0.25, p = 0.64).  
  





Figure 3.9: CSF exosomes from DLB and PD patients induce the aggregation of soluble α-Synuclein in a cell 
model. (A) Schematic cartoon of the split luciferase complementation assay. Human neuroglioma H4 cells are 
co-transfected with two α-Synuclein constructs, each fused to different luciferase fragments (S1: N-terminal 
part of luciferase, S2: C-terminal part of luciferase). When both luciferase fragments complement due to 
aggregation of α-Synuclein, a luminescence signal is measured indicating induced aggregation of α-Synuclein. 
(B) Transfected H4 cells exhibit a luminescence increase upon treatment with exosomes prepared from equal 
volumes of CSF. Exosomes were derived from patients with DLB (green bar, n = 9), PD (red bar, n = 10) and 
neurological controls (blue bar, n = 7). One-way ANOVA revealed significant difference (p = 0.000513) that was 
further specified by two-sided t-test, * p < 0.05. All measurements were peformed in duplicates. (C) Ratio of 
luminescence increase in H4 cells to α-Synuclein levels in CSF exosomes from patients with DLB (green bar, 
n = 8), PD (red bar, n = 9) and neurological controls (blue bar, n = 6). After normalizing for α-Synuclein content 
in exosomes, DLB and PD derived exosomes cause a significant increase of the luminescence signal in reporter 
cells. One-way ANOVA was applied (p = 0.00698) followed by two-tailed Mann-Whitney U-test, (*) p < 0.10, 
* p < 0.05. All measurements were performed in duplicates. (D) Correlation analysis of luminescence increase 
in H4 cells with CSF exosomal α-Synuclein levels prepared from 1 ml CSF; DLB: green diamonds, n = 8, PD: red 
rectangles, n = 9 and neurological controls: bue triangles, n = 6. Pearson`s correlation coefficient for DLB and 
PD: r = 0.85, p = 1.6 × 10
−5
 and neurological controls: r = −0.25, p = 0.64.  
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3.1.7. Characterization of exosomal α-Synuclein in plasma from patients with 
DLB, PD and neurological controls 
Additionally to the characterization of exosomal α-Synuclein derived from CSF, we focused 
on exosomal α-Synuclein derived from plasma as another source of exosomes. Therefore, 
we selected plasma samples from DLB, PD and neurological control patients from the Kassel 
cohort and purified exosomes from 500 µl total plasma by UC. Further demographic 
information of the analyzed plasma samples is depicted in Table 6.3. 
Exosomes were then analyzed for their α-Synuclein content by ECL assay. Figure 3.10A 
shows the quantification of α-Synuclein levels in exosomes normalized to 1 ml plasma as 
starting material. Here, we did not detect any significant differences in exosomal α-Synuclein 
content between DLB and control plasma or between PD and control plasma [DLB 
mean = 83.30 pg exosomal α-Synuclein, SEM = 29.32 pg exosomal α-Synuclein, n = 9; PD 
mean = 60.95 pg exosomal α-Synuclein, SEM = 12.04 pg exosomal α-Synuclein, n = 23 and 
neurological control mean = 59.73 pg exosomal α-Synuclein, SEM = 9.77 pg exosomal 
α-Synuclein, n = 23; one-way ANOVA revealed no significant differences (p = 0.5723)]. When 
we calculated the ratio of α-Synuclein in exosome preparations to α-Synuclein in total 
plasma, we observed that 0.2% – 0.3% of total plasma α-Synuclein is associated with 
exosomes with a tendency to a lower ratio in patients with DLB. However, no significant 
differences between the patient groups were detected (Figure 3.10B, DLB mean = 0.21%, 
SEM = 0.018%, n = 9; PD mean = 0.30%, SEM = 0.037%, n = 23 and neurological control 












Figure 3.10: Characterization of exosomal α-Synuclein in plasma from patients with DLB, PD and neurological 
controls. (A) Quantification of plasma exosomal α-Synuclein derived from DLB, PD and neurological control 
samples, which were obtained from the Kassel cohort. DLB: green bar (n = 9), PD: red bar (n = 23) and 
neurological controls: blue bar (n = 23). One-way ANOVA (p = 0.5732) revealed no significant differences.  
(B) Ratio (in %) of α-Synuclein levels in exosomes to α-Synuclein levels in total plasma in DLB patients (green 
bar, n = 9), PD patients (red bar, n = 23) and neurological controls (blue bar, n = 22). For statistical analysis, one-
way ANOVA was applied, p = 0.3065 (n.s.). All values are given as mean ± SEM. 
 
 
3.1.7.1. Plasma exosomes and exosomal α-Synuclein purified by SEC are suitable for 
quantitative analysis 
In addition to the UC based isolation method, we used SEC purification as a second approach 
to isolate plasma exosomes since several disadvantages of the UC purification have been 
observed. A reliable quantification of exosome numbers in both, total plasma and the UC 
pellet is not possible by using NTA due to the abundance of lipoproteins and IgG complexes 
of similar size in total plasma which might be co-isolated with exosomal vesicles in the UC 
pellet (Boing et al., 2014), thus making it impossible to discriminate between protein 
complexes and exosomes. Furthermore, UC leads to aggregation of exosomes, which might 
interfere with the correct analysis of exosome concentrations in the pellet. Another 
challenge is the lack of purity of blood derived UC exosomes since they were found to be 
contaminated with albumin and protein complexes (Boing et al., 2014).  
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For SEC purification, 1 ml plasma was subjected to serial centrifugation rounds as described 
in section 2.2.3.2. The supernatant of the 10,000 x g step was loaded on the SEC column and 
24 fractions (500 µl each) were collected and analyzed for particle numbers by NTA and their 
total protein content by NanoDrop spectrophotometer (Figure 3.11A). For the quantification 
of exosome numbers, fractions were measured six times in a 1:800 dilution. The majority of 
particles in the size range of exosomes (≤ 120 nm) eluted in SEC fractions 9 – 12 (red line) 
whereas total protein amounts started to increase from fraction 12 on and reached their 
highest levels in fractions 21 and 22 (blue line) (Figure 3.11A). This was further supported by 
WB analysis of SEC fractions derived from 1 ml plasma and immunostained against human 
IgG as an abundant protein in total plasma (Figure 3.11C). IgG was detected in total plasma 
and in SEC fractions 12 – 24 as well as in the UC pellet indicating partial co-purification of IgG 
via UC. In contrast, lower SEC fractions 7 – 11 were found to be free of IgG (Figure 3.11C). 
We therefore decided to collect fractions 8 – 11 as the purest fractions containing exosomes. 
For α-Synuclein quantification fractions were pooled as follows: 1 – 4, 5 – 8, 9 – 12, 13 – 16 
and 17 - 24. Quantification of α-Synuclein protein revealed a total of 11.6 pg in fraction pool 
9 - 12, which was the exosome containing pool, compared to fractions 1 - 4 (0 pg 
α-Synuclein), fractions 5 – 8 (6.18 pg α-Synuclein) and fractions 13 – 16 (10.5 pg α-Synuclein) 
(Figure 3.11B). However, the highest level of α-Synuclein was measured in fraction pool 
17 - 24 (422.8 pg α-Synuclein) indicating that the majority of α-Synuclein in total plasma is 
non-vesicle associated but rather consists of free α-Synuclein species which elute later and 
are therefore found in in higher SEC fractions. This was further confirmed by the ratio of 
exosomal α-Synuclein (fraction 8 – 11) to total plasma α-Synuclein content (Figure 3.11D). 
Only 0.27% (± 0.15%) of overall α-Synuclein in total plasma was found in association with 
exosomes. This ratio is comparable to our previous findings with plasma exosomes purified 
by UC (see also 3.1.7 and Figure 3.10B).  
 
  





Figure 3.11: Purification of exosomes from plasma by size exclusion chromatography (SEC). (A) 1 ml plasma 
was first cleared from cellular debris and larger plasma membrane derived vesicles and then loaded on a SEC 
column. Particle numbers in the size range of exosomes of each SEC fraction were quantified by NTA (red line) 
and the total protein concentration of each fraction was measured by NanoDrop spectrophotometer (blue 
line). (B) α-Synuclein protein levels of pooled SEC fractions 1 – 4, 5 – 8, 9 – 12, 13 – 16 and 17 – 24 derived from 
1 ml plasma were quantified by ECL assay with fractions 9 – 12 as the exosome pool according to NTA results in 
A . The y-axis was splitted into two segments due to the high α-Synuclein level in fraction pool 17 – 24. (C) WB 
analysis of SEC fractions derived from 1 ml plasma, total plasma and the UC preparation from 1 ml of the same 
sample. Samples were stained against the high abundant total plasma protein IgG to verify purity of the 
exosome pool (D) The ratio of α-Synuclein levels in exosomes purified by SEC (fractions 8 – 11) to α-Synuclein 
levels present in total plasma is given in %. (E) The CV was calculated for the number of exosomes and 
α-Synuclein protein levels in SEC purified exosome pool (fraction 8 – 11). Here, n = 5 biological replicates from 
one plasma donor were purified by SEC and analyzed on 5 different days. Values are given as mean or 
mean ± SEM. 
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As described above, accurate quantification of exosome numbers by NTA was challenging 
when using UC preparation due to the presence of lipoproteins displaying a similar size as 
exosomes. By using SEC, exosome numbers analyzed in the exosome containing fractions 
8 - 11 resulted in a CV of 22% (Figure 3.11E, left bar) and the CV for exosomal α-Synuclein 
levels revealed a value of 6.84%. (Figure 3.11E, right bar). The CVs were calculated from 
5 biological replicates of one plasma sample. 
These findings indicate that exosomes purified via the SEC method now allow reliable 
quantification of exosome numbers and exosomal α-Synuclein levels. 
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3.2. Small ncRNAs in CSF exosomes as a potential biomarker in AD 
In the second part of the study we evaluated the potential of CSF exosomal small ncRNA 
species to discriminate AD from controls without neurodegeneration. We first asked 
whether exosomal RNA reflects the intracellular RNA composition and may therefore be 
suitable as a potential biomarker candidate. The potential of CSF exosomal small ncRNAs as 
a diagnostic biomarker was tested with a cohort of AD patients and psychiatric controls 
without dementia or other neurodegenerative diseases.  
Of note, since a patent application for CSF exosomal small ncRNAs as a biomarker in AD is in 
preparation, the small ncRNA signatures of exosomes derived from primary cortical and 
hippocampal neurons as well as from AD and neurological control CSF are not shown in this 
thesis. 
 
3.2.1. Exosomal small ncRNA content reflects neuronal small ncRNA composition 
First, we determined the small ncRNA composition in exosomes and compared it to that of 
the corresponding parent cell line. For this purpose, exosomes were purified from medium 
of primary mouse cortical or hippocampal neuronal cultures. Purification was performed 
according to the UC protocol (see section 2.2.3.1) and cell lysates were prepared in parallel 
(see section 2.2.5.3) followed by extraction of total RNA from exosome preparations and cell 
lysates using TriReagent based protocols. Samples were then subjected to small RNA NGS 
sequencing.  
When plotting the small ncRNA expression levels in exosomes derived from cortical neurons 
against the cellular small ncRNA expression levels we found a strong correlation (Figure 
3.12A, Pearson`s correlation R2 = 0.98, p < 10−5) indicating that the exosomal RNA 
composition is very similar to the intracellular RNA of the parental cell. Similar results were 
obtained in exosomes derived from hippocampal neuron cultures as depicted in Figure 3.12B 








Figure 3.12: Small ncRNA composition in exosomes partially reflects that one of the parental cell. Scatterplots 
displaying correlations between small ncRNA expression levels in exosomes derived from primary cortical 
neurons and ncRNA expression levels in corresponding cells (A) or between small ncRNA expression levels in 
exosomes derived from primary hippocampal neurons and those of the parental cells (B). Each dot represents 
an individual small ncRNA and Pearson`s correlation was applied for statistical analysis. Correlation coefficient 
R
2
 = 0.98, p < 10
−5
 for (A) and correlation coefficient R
2
 = 0.98, p < 10
−5
 for (B). 
 
Despite the fact that several small ncRNAs were found to be differentially expressed in 
exosomes compared to the parent cell (data not shown), the overall composition of small 
ncRNAs in exosomes represented that of the corresponding cell. Thus, exosomes might be 
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3.2.2. CSF exosomal small ncRNA signatures as a potential diagnostic biomarker 
for AD 
The next step was to test whether the exosomal RNA composition could be used for 
diagnostic purposes to distinguish between AD and controls. To this end, CSF exosomal small 
ncRNA from a cohort composed of 24 AD patients and 18 controls (for detailed description 
of the cohort refer to section 2.2.2.3 and Table 6.4) was sequencend followed by the analysis 
of differentially expressed small ncRNAs (Figure 3.13A for experimental design). Initially, the 
exosomal RNA of 31 AD and 19 control samples was sequenced but 7 AD and 1 control 
sample were not usable for bioinformatic analyses due to poor RNA quality. These samples 
were filtered out since their library size was below 100,000 reads. 
Based on RNA expression levels, sample classification was performed by using machine 
learning algorithm approach in combination with statistical methods to achieve the selection 
of a specific combination of small ncRNAs. This set of selected small ncRNAs was further 
used to develop an algorithm that allows the discrimination of AD patients from controls. 
The final data set was then trained and tested with an independent replication cohort that 
comprised 21 AD and 20 control samples (for further information see section 2.2.2.3 and 
Table 6.5). The initial cohort comprised 37 AD and 34 control samples and was reduced to 21 
AD and 20 control samples after quality filtering for library size. 
The performance during training and testing is depicted in Figure 3.13B and resulted in an 
AUC value of 0.83 during testing indicating that the final small ncRNA signature achieved 
high accuracy (Figure 3.13C).  
This indicates that the identified small ncRNA signature in human CSF may in principle be 
suitable to distinguish between AD patients and psychiatric controls with an accuracy similar 
to that of the approved diagnostic CSF markers Aβ42, Tau and phospho-Tau. 
 
  





Figure 3.13: CSF exosomal small ncRNA signature to differentiate AD from controls. (A) Schematic overview 
of the generated pipeline to evaluate the potential of CSF exosomal small ncRNA signatures to distinguish 
between AD and controls. Bioinformatic analyses were developed and performed by Gaurav Jain (under 
supervision of Prof. Dr. André Fischer, DZNE Göttingen). (B) Violin plot demonstrating performance of the 
replication cohort during training and testing of the selected data set. (C) ROC curve analysis of the replication 
cohort was performed to examine the diagnostic performance of CSF exosomal small ncRNAs to discriminate 
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4. Discussion 
4.1. Characterization of CSF exosomal α-Synuclein in patients with 
α-Synuclein related neurodegeneration 
In this study, we aimed to characterize exosomal α-Synuclein in different patient groups 
including α-Synuclein related neurodegeneration (PD and DLB), neurological controls with a 
non-α-Synuclein related Pakinson syndrome (PSP), and non-neurodegenerative controls by 
quantifying exosomal α-Synuclein levels and exosome numbers in CSF. Here, we provide 
evidence that CSF exosomal α-Synuclein may allow the discrimination between α-Synuclein 
related neurodegeneration and non-α-Synuclein related Parkinson syndrome. Therefore, 
exosomal α-Synuclein bears the potential as a diagnostic biomarker in the future, replication 
provided.  
Moreover, we were able to show that CSF derived exosomes from patients with PD and DLB 
have an increased potential to cause the induction of α-Synuclein aggregation compared to 
those from neurological controls. This finding may provide more insight on the spreading of 
α-Synuclein pathology. 
 
4.1.1. Induction of α-Synuclein aggregation by CSF exosomes 
4.1.1.1. Exosomes as carriers for pathogenic proteins 
It has been previously shown that exosome-like MVs can be enriched in aggregation-prone 
proteins such as PrP, Aβ, Tau, and α-Synuclein (Bellingham et al., 2012b; Fevrier et al., 2004; 
Saman et al., 2012; Sharples et al., 2008). Several in vitro studies demonstrated exosomal 
α-Synuclein release, transfer, and uptake into recipient cells (Danzer et al., 2012; 
Emmanouilidou et al., 2010). Recently, we were able to report that exosomal α-Synuclein is 
present in the CNS in vivo (Kunadt et al., 2015). 
Within this study, we demonstrate that exosomal α-Synuclein can be isolated from human 
CSF where it is accessible for quantification (section 3.1.1 and Figure 3.2). By using a reporter 
cell assay, PD exosomes show a two-times higher aggregate inducing activity when 
exosomes prepared from equal CSF volumes were added to the reporter cells. Since we 
observed that CSF from DLB patients contains lower overall numbers of exosomes compared 
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to PD patients and neurological controls it was not surprising that DLB and control exosomes 
purified from equal CSF volumes do not differ in their α-Synuclein aggregate inducing activity 
(Figure 3.9B). However, when adjusting for exosomal α-Synuclein levels in the preparations, 
exosomes from PD and DLB patients exhibit a similar and approximately two times higher 
potential to induce aggregation of soluble α-Synuclein in recipient cells compared to 
exosomes from neurological controls. Moreover, exosomal α-Synuclein levels strongly 
correlate with their potential to induce α-Synuclein aggregation in the case of DLB and PD 
but not for exosomes derived from the control group. This indicates that exosomes from DLB 
and PD may contain a pathogenic species of α-Synuclein.  
Our findings suggest (i) that exosomes isolated from human CSF carry bioactive α-Synuclein 
molecules, which are internalized into neuronal cells in an in vitro model and (ii) that 
exosomes from DLB and PD CSF contain a pathogenic α-Synuclein species that is able to 
induce aggregation of soluble α-Synuclein.  
It was demonstrated previously in vivo that exosomes can be taken up into neurons where 
their cargo proteins and RNA molecules are functionally active (El Andaloussi et al., 2013; 
Fruhbeis et al., 2013). It is possible that a pathogenic misfolded α-Synuclein species is 
preferentially sorted into exosomes in DLB and PD followed by the exosomal transfer and 
uptake into a healthy neuron. Interestingly, it has been previously suggested that higher-
order oligomerization targets proteins for EV release as demonstrated with the cytoplasmic 
protein TyA in Jurkat T cells (Fang et al., 2007). Moreover, antibody-induced aggregation of 
the transferrin receptor enhanced its sorting into MVBs in maturing reticulocytes (Vidal et 
al., 1997). Thus, in the case of PD and DLB, oligomerization and aggregation of misfolded 
α-Synuclein could favour its uptake into exosomes.  
Observations from in vitro and in vivo studies could demonstrate that endogenous 
α-Synuclein can move to healthy neurons (Desplats et al., 2009), exogenous α-Synuclein 
oligomers and fibrils are taken up by recipient cells and cause seeding of neuronal 
α-Synuclein aggregation (Hansen et al., 2011; Luk et al., 2009; Volpicelli-Daley et al., 2011), 
suggesting intercellular propagation of pathogenic α-Synuclein in a prion-like manner. It is 
possible that pathogenic α-Synuclein aggregates may be released in exosomes and act as a 
seed for α-Synuclein aggregation in recipient cells. Importantly, Danzer et al. (2012) have 
provided evidence that oligomeric forms of α-Synuclein are even more efficiently 
internalized into neuronal cells when they are incorporated into exosomes.  
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Overall, cell-to-cell transfer of α-Synuclein via exosomes could contribute to the spreading of 
α-Synuclein pathology in a stereotypical anatomical pattern along axonal projections as 
observed in α-Synuclein related neurodegeneration (Braak et al., 2003; Lee et al., 2012; Luk 
et al., 2012; Ulusoy et al., 2013). 
To date, the role of exosomes in neurodegeneration is still elusive and besides their 
proposed disease-driving role, exosomes are suggested to exhibit neuroprotective functions 
by acting as scavengers in order to remove pathogenic or harmful molecules from the cell 
under physiological as well as pathological circumstances. Interestingly, impairment of 
cellular degradation pathways, as autophagy, seems to play a role in insufficient α-Synuclein 
clearance in PD and DLB (Crews et al., 2010; Rockenstein et al., 2005). Furthermore, 
α-Synuclein release via exosomes was observed to be increased when the autophagy 
pathway is blocked in vitro (Alvarez-Erviti et al., 2011; Danzer et al., 2012).  
Extracellular Aβ has been found to attach to the surface of exosomes in vitro (Rajendran et 
al., 2006) and N2a cell derived exosomes injected into mouse brains were reported to 
capture Aβ and further favor its clearance by microglia, thus suggesting a role of exosomes 
in Aβ clearance (Yuyama et al., 2014). The authors further suggest that extracellular Aβ 
might be trapped to exosomes by binding to glycosphingolipids expressed on the exosomal 
surface (Yuyama et al., 2014). However, this scenario is unlikely for pathogenic α-Synuclein 
since α-Synuclein was found to localize to the lumen of exosomes rather than being attached 
to the surface membrane (Kunadt et al., 2015). Nevertheless, neurons could release 
pathogenic α-Synuclein species via the exosomal pathway to protect cell integrity. Indeed, 
exosomes are able to eliminate toxins from cells and deliver these molecules to the 
extracellular space, e.g. as shown previously with the Staphylococcus aureus α-toxin 
(Husmann et al., 2009). 
Thus, exosomes could represent an alternative route to relieve the cell of excess or toxic 
α-Synuclein molecules and deliver those to microglial cells. Notably, exosomes are more 
efficiently taken up by microglia than by neurons (Fitzner et al., 2011; Fruhbeis et al., 2013; 
Zhuang et al., 2011). However, possible microglia dysfunction, as observed in the course of 
many neurodegenerative diseases (Luo et al., 2010), could contribute to exosomal 
α-Synuclein spreading to other neurons rather than mediating its degradation via exosome 
uptake into microglia.  
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4.1.1.2. Seeding capacity of exosomes 
By using the split-luciferase protein fragment complementation assay, we could 
demonstrate that isolated CSF exosomes from DLB and PD patients exhibit the capacity to 
induce aggregation of soluble α-Synuclein (Figure 3.9). Evidence of exosomal seeding 
activities on endogenous proteins was recently provided from studies on the dissemination 
of Tau pathology (Polanco et al., 2016). Here, the authors demonstrated that exosomes 
derived from Tau transgenic mice are enriched in mutant Tau and are able to initiate the 
aggregation of soluble Tau compared to exosomes derived from wild-type mice in a FRET 
biosensor cell model. Interestingly, induction of Tau aggregation seems to be threshold 
dependent as reflected by the observation that only cells with a high level of exosome 
uptake showed Tau aggregation.  
We observe that the aggregation inducing activity of PD and DLB exosomes correlates 
linearily with the levels of exosomal α-Synuclein (Figure 3.9D). Additionally, we find that only 
a small portion of approximately 2% of CSF total α-Synuclein is associated with exosomes 
(Figure 3.3C). However, exosomal α-Synuclein aggregates were taken up into cells more 
efficiently than free extracellular α-Synuclein oligomers (Danzer et al., 2012) and a 
pathological confirmation of α-Synuclein could induce the templated conversion of soluble 
α-Synuclein in target cells. Moreover, exosomes were recently suggested to exhibit catalytic 
effects on the α-Synuclein aggregation process by reducing the lag time and therefore 
facilitating aggregation of synthetic α-Synuclein in vitro (Grey et al., 2015). Also, the authors 
claimed that gangliosides in the exosomal membrane are sufficient for catalyzing 
α-Synuclein aggregation. In fact, we cannot claim that the α-Synuclein aggregation inducing 
activity of PD and DLB exosomes exclusively depends on the exosomal α-Synuclein species.  
Since exosomal α-Synuclein levels do not differ between PD and controls in the Kassel cohort 
(Figure 3.4), the difference in the aggregation inducing activity between PD and control 
exosomes could be due to a pathogenic α-Synuclein species in PD exosomes. According to 
our hypothesis, a pathogenic seed, whose actual nature is unknown, would be required in 
exosomes to initiate the aggregation of endogenous α-Synuclein in healthy cells. This 
assumption needs to be further investigated by experimental studies including identification 
of the α-Synuclein species in DLB and PD exosomes compared to control exosomes and 
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further analyses on whether this species can induce conversion of endogenous α-Synuclein 
monomers into a misfolded state. 
 
 
4.1.2. CSF exosomal α-Synuclein as a potential biomarker for α-Synuclein related 
diseases 
4.1.2.1. Quantification of exosomal α-Synuclein and exosome numbers 
In this work, we show that exosomal α-Synuclein is present in CSF and that exosomal 
α-Synuclein levels and CSF exosome numbers can be quantified (Figure 3.2). Multiple studies 
have already focused on the quantification of α-Synuclein amount in total CSF and plasma in 
attempt to study this parameter as a potential marker to diagnose PD or other α-Synuclein 
related disorders. However, reports resulted in inconsistent observations and the diagnostic 
value was limited due to overlaps with α-Synuclein levels of control groups (Vella et al., 
2016; Wennstrom et al., 2013). 
When studying CSF α-Synuclein levels in patients with an early stage of PD, in the DeNoPa 
cohort, we find slightly reduced α-Synuclein levels in total CSF as well as in exosomes 
compared to healthy controls (Figure 3.3A,B). This finding is in contrast to our observation of 
more progressed disease stages in the Kassel cohort, where no differences are detected 
between the PD group and the control groups (compare Figure 3.4). The discrepancy in our 
two cohorts could be given by the different control groups, which consisted of healthy 
control patients who did not show any movement disorder in the case of the DeNoPa cohort 
and patients suffering from polyneuropathy in the Kassel cohort. Although the latter group 
was negatively tested for PD by clinical methods including standardized Levodopa testing, 
smell test and brainstem ultrasound, we cannot fully exclude that a minor part of these 
patients already had an early stage of PD. Moreover, some of the PNP patients also showed 
a tremor which has recently been shown to precede the clinical diagnosis of PD (Schrag et 
al., 2015). In addition, it might be possible that the relatively small sample number of the 
Kassel cohort controls (n = 15) compared to the sample number of the healthy control group 
of the DeNoPa cohort (n = 58) resulted in a lack of significant differences within exosomal 
α-Synuclein levels between PD and neurological controls. 
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The finding of significant lower exosomal α-Synuclein levels in DLB patients compared to PD 
and the two control groups (Figure 3.4A) is most likely caused by the reduced absolute 
number of exosomes in DLB CSF compared to all other tested groups (Figure 3.7A). However, 
we also detect decreased α-Synuclein protein concentrations in total CSF from DLB patients, 
which is in contrast to findings of other studies that report no differences between DLB, PD 
and controls (Aerts et al., 2012; Reesink et al., 2010).  
Interestingly, the levels of exosomal α-Synuclein increase in more progressed stages of DLB, 
indicated by the finding that elevated exosomal α-Synuclein levels are paralleled by impaired 
cognitive function and elevated CSF levels of the neuronal injury marker Tau (Figure 3.5). Tau 
is an axonal enriched protein that stabilizes microtubules and therefore maintains the 
morphology of neurons (Ballatore et al., 2007). It is likely that damaged neurons release Tau 
proteins, which in turn can be transported to the CSF. Consequently, elevated CSF total Tau 
levels could mirror neuronal damage and are therefore considered as an unspecific marker 
for neurodegenerative processes, as reported for AD and DLB (Mollenhauer et al., 2005; 
Montine et al., 2010; Musiek and Holtzman, 2012). We suggest that higher levels of 
exosomal α-Synuclein in later disease stages could reflect an increased disease activity in 
DLB patients since it is possible that an increasing number of neurons contain pathogenic 
α-Synuclein species during the disease course, which in turn could be released within 
exosomes. As a consequence, the higher number of neurons bearing pathological 
α-Synuclein could then contribute to the rise of exosomal α-Synuclein levels in CSF. 
According to this, it would be important to study whether neurons release more exosomes 
enriched with α-Synuclein during disease progression compared to control neurons. 
However, a correlation between disease progression and CSF exosomal α-Synuclein levels is 
not observed in PD. Here, exosomal α-Synuclein levels do not correlate with the severity of 
motor symptoms (Figure 3.6). 
The correlation between increasing exosomal α-Synuclein levels with disease progression 
and neurodegeneration is in contrast with the finding of overall lower exosomal α-Synuclein 
levels in the DLB group compared to all other groups. We hypothesize that exosome 
numbers and hence exosomal α-Synuclein levels in DLB CSF decrease at the beginning or in 
early stages of the disease and increase again during later stages. The initially low levels of 
exosomal α-Synuclein and exosome numbers could display a cellular clearance deficit for 
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α-Synuclein in DLB, which could further contribute to the formation of intracellular 
α-Synuclein deposits. 
 
4.1.2.2. Preliminary evaluation of CSF exosomal α-Synuclein as a biomarker  
By using exosomal α-Synuclein levels as well as the ratio of exosomal α-Synuclein levels to 
the number of exosomes we are able to discriminate between α-Synuclein related Parkinson 
syndrome and neurological controls, in a small pilot study. Specificity and sensitivity for the 
discrimination of DLB, PD and controls are high as demonstrated by ROC curve analysis 
(Figure 3.8, Table 3.3 and Table 3.4). Of note, since we additionally find that increasing CSF 
exosomal α-Synuclein levels in DLB are strongly paralleled by cognitive decline and 
neurodegeneration in later disease stages, we suggest that CSF exosomal α-Synuclein could 
also display a potential surrogate marker to monitor disease progression in DLB patients. 
Such markers are still missing, nevertheless longitudinal observations are clearly needed to 
evaluate the prognostic performance of exosomal α-Synuclein in DLB CSF.  
Overall, we provide here the first evaluation of exosomal α-Synuclein as a CSF biomarker for 
PD and DLB. Since patient numbers are relatively low in the cohort used for analysis, the 
cohort was monocentric and an independent validation cohort is missing, replication in a 
larger cohort, ideally derived from different centers, is required for further analysis to define 
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4.1.3. Methodological considerations regarding EV purification for α-Synuclein 
quantification in CSF and plasma 
A prerequisite before an application as a clinical biomarker for patient stratification or 
outcome measurement is (i) to further optimize and validate a sample preparation 
technique which allows easy, fast and reliable purification and quantification of exosomes 
with low intertest and intersite variability, (ii) the validation of our previous findings in a 
larger and independent cohort and (iii) to expand our approach to plasma in addition to CSF.  
The preparation of plasma exosomes with the most commonly used UC method has so far 
been hampered by a high variation of exosome yields and a tremendous difficulty to 
quantify exosome numbers in the resulting vesicle fraction, due to clogging of the vesicles 
after UC. In addition, blood derived exosome preparations lack a satisfying purity and 
contain contaminants of lipoproteins, albumin and protein complexes. To overcome these 
obstacles, we have established size exclusion chromatography  preparations from CSF and 
plasma exosomes, using commercially available SEC columns (qEV, Izon) which are based on 
Boing et al. (2014).  
This approach results in preparations of superior purity, gives highly reproducible results and 
can be performed without expensive equipment and with the settings of a routine diagnostic 
laboratory. Another major advantage of the SEC method is the possibility to directly quantify 
exosome yields of the preparations by standardized NTA. In contrast, the previously 
employed UC method did not allow the measurement of exosome yields and we had to refer 
to exosome numbers of the unprocessed CSF. Thus, in the previous approach, employing the 
UC method, we could not correct for differences in exosome preparation yields, which 
added another factor of variation. Of note, the coefficient of variance of this method was 
22% (Figure 3.2C), which can now be considerably improved by the SEC approach.  
When we used the UC method to isolate exosomes from human plasma, we do not detect 
differences of exosomal α-Synuclein levels between DLB, PD and neurological control 
patients selected from the Kassel cohort (Figure 3.10A). Quantification of exosome numbers 
by using NTA was not possible due to the presence of lipoproteins and protein complexes 
that are indistinguishable from exosomes by common particle quantification methods. In 
contrast, SEC purification of plasma exosomes results in exosome preparations of high purity 
with low non-exosomal protein contaminations (Figure 3.11A,C).  
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In contrast to CSF, where approximately 2% of total CSF α-Synuclein is localized to the 
exosome fraction, only 0.3% of total plasma α-Synuclein is found in exosomes (Figure 3.11D). 
This ratio is comparable to our findings obtained from UC exosome preparations (Figure 
3.10B). Importantly, we demonstrate that SEC plasma exosomes are suitable for 
quantification of exosome numbers as well as exosomal α-Synuclein levels. The coefficient of 
variance calculated from five biological replicates reveals values of 6.8% for exosomal 
α-Synuclein content and 22% for the quantification of exosome numbers in the pure 
exosome fraction (Figure 3.11E).  
In conclusion, we provide evidence that the SEC approach allows reliable purification and 
further quantification of plasma exosomes to better characterize exosomal α-Synuclein in 
patients with α-Synuclein related neurodegeneration compared to controls.  
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4.2. Preliminary evaluation of CSF exosomal small ncRNAs as a 
biomarker for AD 
In the second study, we investigated the small ncRNA composition of CSF derived exosomes 
to test whether exosomal ncRNAs could be used to distinguish AD from cognitively healthy 
controls. 
 
4.2.1. Exosomes partially mirror the cellular small ncRNA composition 
Experimental studies from brain tissue or body fluids have provided evidence that the 
expression pattern of small ncRNAs is dysregulated in neurodegenerative diseases including 
AD and PD, suggesting that these RNA species play an important regulatory role in disease 
onset and progression (Goodall et al., 2013; Kumar et al., 2013; Schipper et al., 2007; Smith 
et al., 2011). Hence, CSF and blood have been screened for changes in miRNA expression 
levels in AD patients compared to controls in order to use identified miRNA profiles as a 
diagnostic or prognostic biomarker (Alexandrov et al., 2012; Burgos et al., 2014; Danborg et 
al., 2014; Geekiyanage et al., 2012; Leidinger et al., 2013). Although some 'AD specific' 
miRNAs have been identified, analyses of differentially expressed miRNAs generally result in 
different signatures among studies with a lack of overlap. Challenges and variabilities are 
most likely caused by sample collection, handling, processing, and storing conditions, which 
were suggested to cause differences in the expression levels of specific miRNAs (Femminella 
et al., 2015). Thus, widely used standard operating procedures (SOPs) for sample processing, 
including standardized RNA extraction, are required to minimize intersite variability. 
Since small ncRNA species are also detectable in exosomes that are secreted into body 
fluids, exosomes could provide important information of intracellular processes. Exosomal 
small ncRNA compositions in CSF or plasma could even represent more reliable signatures 
than free small ncRNAs since the exosome content is enclosed by the lipid bilayer membrane 
and therefore protected from degradation, for instance by extracellular RNAses. Moreover, 
the exosomal membrane seems to be highly stable in storing conditions even over long time 
periods (Kalra et al., 2013), consequently providing excellent protection of the encapsulated 
RNA cargo.  
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By using NGS we were able to identify small ncRNA profiles of primary cortical and 
hippocampal neurons and their secreted exosomes. Here, we find that the exosomal RNA 
profile partially overlaps with that of the parental cell and expression levels of a small ncRNA 
subset in exosomes highly correlate with those of the exosome releasing cell (Figure 3.12). 
Thus, small ncRNAs transported into exosomes partially reflect the intracellular ncRNA 
content and could be used as a biomarker. This finding is in contrast to other reports which 
stated that the miRNA expression pattern found in exosomes does not significantly correlate 
with the miRNA composition of the parental cell as described for CD4+ T cells (de Candia et 
al., 2014), Jurkat T cells, and primary DCs (Mittelbrunn et al., 2011). 
 
4.2.2. Selected CSF small ncRNA profile distinguishes between AD and controls 
Recently, Cheng et al. (2015) reported a signature of 17 differentially expressed miRNAs in 
serum derived exosomes from AD patients obtained by NGS sequencing. Further validation 
by quantitative real-time PCR resulted in a set of 16 dysregulated miRNAs in AD compared to 
controls. This miRNA set could predict AD with 87% sensitivity and 77% specificity when risk 
factors as age and apolipoprotein ε4 allele status were included in the analysis (Cheng et al., 
2015), suggesting that miRNA signatures in exosomes could be used as a biomarker. 
Our algorithm, based on the selection of a specific small ncRNA set expressed in CSF 
exosomes, is able to distinguish AD from controls in our replication cohort with high 
accuracy (Figure 3.13). Thus, our data provide evidence that the final set of exosomal small 
ncRNAs has the potential of a “disease signature” for AD that however still needs to be 
replicated in an independent larger validation study.  
Moreover, it is important to study to what extend exosomal small ncRNAs expression levels 
depend on SOPs between different laboratories. 
An ultimate aim is the identification of markers which could predict subsequent AD 
dementia already during preclinical or prodromal disease stages in order to enable 
treatment at the earliest possible time point. Therefore, it is of high interest to study CSF 
exosomal small ncRNA signatures in MCI patients with and without a later conversion to AD 
dementia and to compare their profiles to those found in AD patients.  
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4.3. Conclusions 
4.3.1. Characterization of CSF exosomal α-Synuclein 
The work from section 3.1 presents a comprehensive analysis of α-Synuclein in CSF 
exosomes from different diseases with α-Synuclein related and non-related 
neurodegeneration. CSF exosomes from patients with α-Synuclein related 
neurodegeneration (DLB and PD) exhibit the capacity to induce aggregation of soluble 
α-Synuclein in an in vitro model. We therefore suggest that DLB and PD exosomes contain a 
pathogenic α-Synuclein species. The ability to induce α-Synuclein aggregation correlates 
linearily with the α-Synuclein content in CSF exosomes from these patients, which is not the 
case for control derived exosomes. This supports the hypothesis that exosomes might 
function as carriers for interneuronal transmission of α-Synuclein pathology in 
synucleinopathies. Taken together, these data might shed light on the mechanism of 
α-Synuclein transmission between cells in PD and DLB and are therefore relevant for disease 
pathogenesis. To expand our findings, further studies are needed, including analysis of the 
α-Synculein species in DLB and PD exosomes compared to exosomes from controls.  
In addition, we showed that the measurement of three parameters, exosomal α-Synuclein, 
exosome numbers and the ratio of exosomal α-Synuclein to exosome numbers is necessary 
to characterize disesase specific differences. Importantly, the amount of CSF exosomal 
α-Synuclein correlates with impaired cognitive function and increased CSF Tau levels as a 
general marker for neurodegeneration in patients with DLB. Hence, we suggest that CSF 
exosomal α-Synuclein levels and the number of CSF exosomes can be used as (i) a diagnostic 
marker to distinguish between DLB, PD and neurological controls and as (ii) a progressive 
marker to monitor disease course in DLB. The diagnostic performance has to be validated in 
a larger and independent cohort for any further biomarker applications.  
Moreover, by using SEC purification, it is now possible to study and characterize α-Synuclein 
in exosomes derived from plasma of patients with α-Synuclein related neurodegeneration 
and neurological controls. 
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4.3.2. CSF exosomal small ncRNAs as a potential biomarker in AD 
The experimental study described in section 3.2 aimed to investigate whether small ncRNA 
content isolated from CSF derived exosomes could be suitable to differentiate AD from 
cognitively healthy psychiatric controls.  
First, we show that small ncRNA profiles found in exosomes partially reflect the small ncRNA 
composition of parental cells, demonstrating that identification of exosomal small ncRNAs 
provides insight into intracellular processes, which could be relevant for the pathogenesis of 
neurodegenerative diseases such as AD. Moreover, we demonstrate that CSF exosomal small 
ncRNAs can be used to differentiate patients with AD from control subjects with no signs of 
neurodegeneration by applying a newly developed statistical model that is entirely based on 
a specific set of differentially expressed exosomal small ncRNAs. A small patient cohort was 
used for testing and training of the model which revealed a high AUC value. To further 
elucidate its potential impact as a diagnostic biomarker in AD, this model needs to be further 
validated in a larger and independent patient cohort. 
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6. Appendix 
6.1. Demographics of CSF and plasma samples used for the analysis 
of α-Synuclein in exosomes 
 
Table 6.1: Demographics of analyzed CSF samples of the DeNoPa cohort 
Mean ± standard deviation (range) Parkinson`s disease healthy Controls 
numbers 76 58 
age (years) 65 ± 8.8 (40–84) 66 ± 6.4 (52–84) 
gender (female/total) 0.65 0.65 
duration of disease (months) 22 ± 27 (4–210) not defined 
Hoehn and Yahr stage 1.7 ± 0.6 (1–3) not defined 
Mini-Mental State Examination  
(MMSE) 
28.6 ± 1.3 (23–30) 28.7 ± 1.2 (26–30) 
 
 
Table 6.2: Demographics of analyzed CSF samples of the Kassel cohort 
Mean ± standard 
deviation (range) 
PD PNP PSP DLB1 
numbers 37 15 25 35 
age (years) 73 ± 7.9 (51–84) 67 ± 14 (34–84) 70 ± 7 (59–83) 72 ± 6.85 (55–84) 
gender (female/total) 0.7 0.4 0.8 0.4 
duration of disease 
(months) 
77 ± 71  
(10–300) 
69 ± 79  
(9–240) 
53 ± 36  
(12–120) 
60 ± 80  
(12–140) 
Hoehn and Yahr stage 3.9 ± 1.2 (1–5) not defined not defined not defined 
Levodopaequivalent 
dosage (mg)2 
557 ± 496  
(0–2000) 
not defined not defined not defined 
Mini-Mental State 
Examination (MMSE) 
not defined not defined not defined 18 ± 6.73  
(5–27) 
1 3 of 35 CSF samples were collected at the Göttingen site 
2 Tomlinson et al. (2010): Systematic review of levodopa dose equivalency reporting in 
Parkinson's disease 
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Table 6.3: Demographics of analyzed plasma samples of the Kassel cohort 
Mean ± standard 
deviation (range) 
PD DLB Neurol. 
Controls 
numbers 23 9 23 
age (years) 73 ± 8.3 (51–83) 73 ± 6.3 (63–84) 70 ± 10.8 (34–84) 
gender (female/total) 0.3 0.7 0.4 
duration of disease 
(months) 
98 ± 85  
(11–336) 
60 ± 20  
(24–96) 
71 ± 60  
(24–240) 
Hoehn and Yahr stage 3.6 ± 1.2 (1–5) 3.6 ± 0.8 (3–5) not defined 
Mini-Mental State 
Examination (MMSE) 
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6.2. Demographics of CSF samples used for small RNA sequencing 
 
Table 6.4: Demographics of analyzed CSF samples of the test cohort 
Mean ± standard deviation (range) Alzeimer`s disease Controls 
numbers 24 18 
age (years) 72 ± 6.4 (60–84) 61 ± 8.4 (48–77) 
gender (female/total) 0.5 0.67 
Mini-Mental State Examination  
(MMSE) 
22.6 ± 5.0 (8–28) not defined 
Depression/total not defined 0.61 
 
 
Table 6.5: Demographics of analyzed CSF samples of the replication cohort 
Mean ± standard deviation (range) Alzeimer`s disease1 Controls2,3 
numbers 21 20 
age (years) 71 ± 7.9 (53–81) 67 ± 9.7 (53–84) 
gender (female/total) 0.33 0.55 
Mini-Mental State Examination  
(MMSE) 
23.7 ± 2.7 (17–28) not defined 
Depression/total not defined 0.45 
 
1 2 of 21 CSF samples were collected at the Tübingen site 
2 4 of 20 CSF samples were collected at the Tübingen site and 6 samples at the Kassel site 
3 7 controls were obtained from healthy subjects without any neurological disorder. 
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